<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">87253</article-id><article-id pub-id-type="doi">10.7554/eLife.87253</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.87253.2</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Differential translation of mRNA isoforms underlies oncogenic activation of cell cycle kinase Aurora A</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-308582"><name><surname>Cacioppo</surname><given-names>Roberta</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3048-9444</contrib-id><email>rc781@cam.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-308583"><name><surname>Akman</surname><given-names>Hesna Begum</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-308584"><name><surname>Tuncer</surname><given-names>Taner</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-75493"><name><surname>Erson-Bensan</surname><given-names>Ayse Elif</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7398-9313</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-138692"><name><surname>Lindon</surname><given-names>Catherine</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3554-2574</contrib-id><email>acl34@cam.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>Department of Pharmacology, University of Cambridge</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/014weej12</institution-id><institution>Department of Biological Sciences, Orta Dogu Teknik Universitesi</institution></institution-wrap><addr-line><named-content content-type="city">Ankara</named-content></addr-line><country>Turkey</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/028k5qw24</institution-id><institution>Department of Biology, Ondokuz Mayis Universitesi</institution></institution-wrap><addr-line><named-content content-type="city">Samsun</named-content></addr-line><country>Turkey</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Topisirovic</surname><given-names>Ivan</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056jjra10</institution-id><institution>Jewish General Hospital</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>29</day><month>06</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>RP87253</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-03-13"><day>13</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-03-13"><day>13</day><month>03</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.03.13.532331"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-05-02"><day>02</day><month>05</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87253.1"/></event></pub-history><permissions><copyright-statement>© 2023, Cacioppo et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Cacioppo et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-87253-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-87253-figures-v1.pdf"/><abstract><p>Aurora Kinase A (AURKA) is an oncogenic kinase with major roles in mitosis, but also exerts cell cycle- and kinase-independent functions linked to cancer. Therefore, control of its expression, as well as its activity, is crucial. A short and a long 3′UTR isoform exist for AURKA mRNA, resulting from alternative polyadenylation (APA). We initially observed that in triple-negative breast cancer, where AURKA is typically overexpressed, the short isoform is predominant and this correlates with faster relapse times of patients. The short isoform is characterized by higher translational efficiency since translation and decay rate of the long isoform are targeted by <italic>hsa-let-7a</italic> tumor-suppressor miRNA. Additionally, <italic>hsa-let-7a</italic> regulates the cell cycle periodicity of translation of the long isoform, whereas the short isoform is translated highly and constantly throughout interphase. Finally, disrupted production of the long isoform led to an increase in proliferation and migration rates of cells. In summary, we uncovered a new mechanism dependent on the cooperation between APA and miRNA targeting likely to be a route of oncogenic activation of human AURKA.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>3′ UTR</kwd><kwd>translation</kwd><kwd>cell cycle</kwd><kwd>miRNA</kwd><kwd>AURKA</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>David James Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Cacioppo</surname><given-names>Roberta</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/R004137/1</award-id><principal-award-recipient><name><surname>Cacioppo</surname><given-names>Roberta</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004410</institution-id><institution>Scientific and Technological Research Council of Turkey</institution></institution-wrap></funding-source><award-id>112S478</award-id><principal-award-recipient><name><surname>Akman</surname><given-names>Hesna Begum</given-names></name><name><surname>Tuncer</surname><given-names>Taner</given-names></name><name><surname>Erson-Bensan</surname><given-names>Ayse Elif</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Post-transcriptional regulation of Aurora Kinase A (AURKA) through alternative polyadenylation of its mRNA determines miRNA influence and is a feature of cell cycle-specific AURKA expression whose impairment leads to acquisition of cancer phenotypes.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Aurora Kinase A (AURKA) is a critical positive regulator of the mitotic phase of the cell cycle (<xref ref-type="bibr" rid="bib72">Willems et al., 2018</xref>). AURKA also plays additional cancer-promoting roles in cell proliferation, survival, migration, and cancer stem cell phenotypes, some of which in interphase and in a kinase-independent manner (<xref ref-type="bibr" rid="bib48">Naso et al., 2021</xref>). AURKA expression follows a strict cell cycle-dependent pattern, with both protein and mRNA levels extremely low in G<sub>1</sub> phase, increasing in S phase, and peaking at G<sub>2</sub> phase until mitosis (<xref ref-type="bibr" rid="bib12">Cacioppo and Lindon, 2022</xref>). High expression of AURKA is strongly associated with cancer progression, drug resistance, and poor prognosis, justifying why oncogenic AURKA represents a renowned target of anticancer drugs (<xref ref-type="bibr" rid="bib18">Du et al., 2021</xref>), and making evident that oncogenic roles of AURKA are prompted by its highly sustained levels of expression.</p><p>AURKA overexpression in human cancers is known to be caused by elevated gene copy number, enhanced transcription, or increased protein stability. Dysregulation of translation is also linked to disease and contributions of dysregulated translation to cancer phenotypes are increasingly reported (<xref ref-type="bibr" rid="bib32">Kovalski et al., 2022</xref>; <xref ref-type="bibr" rid="bib45">Modelska et al., 2015</xref>). Despite some modest evidence suggesting that modulation of AURKA translation is relevant in disease (<xref ref-type="bibr" rid="bib16">Dobson et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Lai et al., 2017</xref>), control of AURKA expression at the level of translation is widely understudied compared with control of its transcription and mRNA processing (<xref ref-type="bibr" rid="bib12">Cacioppo and Lindon, 2022</xref>). For example, it is not clear whether AURKA mRNA undergoes translational activation and/or inhibition during the cell cycle, and the precise timing, extent, or regulators of these processes remain unexplored.</p><p>The process of cleavage of the 3′end of precursor mRNAs (pre-mRNAs) and concomitant addition of a poly(A) tail represents one key event aiding the maturation of mRNAs, termed cleavage, and polyadenylation (C/P) (<xref ref-type="bibr" rid="bib26">Gruber and Zavolan, 2019</xref>). The cleavage site is typically preceded by a polyadenylation signal (PAS), located 10–30 nucleotides (nt) upstream, and by UGUA and U-rich motifs, whereas it is typically followed by U- and GU-rich motifs. Altogether, these elements constitute the C/P site (<xref ref-type="bibr" rid="bib25">Gruber et al., 2016</xref>). Most human pre-mRNAs contain multiple C/P sites (<xref ref-type="bibr" rid="bib15">Derti et al., 2012</xref>), enabling alternative cleavage and polyadenylation (APA) and, thus, distinct expression of transcript isoforms for the same gene. A search using PolyA_DB (<xref ref-type="bibr" rid="bib70">Wang et al., 2018</xref>) indicates the presence of two C/P sites with canonical PASs (AATAAA) on AURKA 3′ untranslated region (3′UTR) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). This fostered our hypothesis that AURKA mRNA could be subjected to tandem 3′UTR APA, resulting in two 3′UTR isoforms that differ in length. It is currently unknown which AURKA PAS is preferentially used in which cellular context or whether a 3′UTR isoform switch can be modulatable.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Increased short/long ratio (SLR) of Aurora Kinase A (AURKA) alternative polyadenylation (APA) isoforms in triple-negative breast cancer (TNBC).</title><p>(<bold>A</bold>) AURKA transcript isoforms (USCS Genome Browser). AURKA gene is located on (-) strand. (<bold>B</bold>) Median and range of SLR values for AURKA 3′UTR obtained using APADetect. Mann–Whitney test; ****p&lt;0.0001. (<bold>C</bold>), (<bold>D</bold>) RT-qPCR analysis of SLR of AURKA 3′UTR in TNBC cell lines (<bold>C</bold>) and patient samples (<bold>D</bold>). SDHA used as reference gene. TN, tissue number. (<bold>E</bold>) Relapse-free survival rates of TNBC patients with high (highest 25%) or low (lowest 25%) AURKA SLRs. p-value determined by log-rank test.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Numerical data for graphs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-87253-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-fig1-v1.tif"/></fig><p>APA is involved in most cellular processes and is often altered in cancer (<xref ref-type="bibr" rid="bib26">Gruber and Zavolan, 2019</xref>). Clinically, human cancers are characterized by unique profiles of alternative 3′UTRs that can be exploited for classification of distinct cancer subtypes (<xref ref-type="bibr" rid="bib61">Singh et al., 2009</xref>; <xref ref-type="bibr" rid="bib71">Wang et al., 2020</xref>), and associations between 3′UTR shortening and poor prognosis (<xref ref-type="bibr" rid="bib36">Lembo et al., 2012</xref>) or drug sensitivity <xref ref-type="bibr" rid="bib75">Xiang et al., 2018</xref> have been detected. At the molecular level, a strong positive association between expression of short 3′UTRs, increased protein levels, and proliferative states has been frequently reported (<xref ref-type="bibr" rid="bib57">Sandberg et al., 2008</xref>; <xref ref-type="bibr" rid="bib42">Mayr and Bartel, 2009</xref>; <xref ref-type="bibr" rid="bib41">Masamha et al., 2014</xref>; <xref ref-type="bibr" rid="bib74">Xia et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Pieraccioli et al., 2022</xref>). Such genome-wide 3′UTR shortening sustains cancer cell behavior by removing repressor sequence elements from the 3′UTR of oncogenic mRNAs, for example, microRNA (miRNA) binding sites (<xref ref-type="bibr" rid="bib57">Sandberg et al., 2008</xref>; <xref ref-type="bibr" rid="bib42">Mayr and Bartel, 2009</xref>; <xref ref-type="bibr" rid="bib41">Masamha et al., 2014</xref>), or alternatively by inactivating tumor suppressors through suppression of their expression (<xref ref-type="bibr" rid="bib35">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Park et al., 2018</xref>).</p><p>The role of miRNAs in regulating cell cycle genes and the relevance of this regulation in cancer are well understood (<xref ref-type="bibr" rid="bib10">Bueno and Malumbres, 2011</xref>; <xref ref-type="bibr" rid="bib21">Ghafouri-Fard et al., 2020</xref>). Few miRNAs have been pointed to as regulators of AURKA mRNA but, importantly, reported cases of miRNA targeting of AURKA occur in those cancers where AURKA overexpression is a promoting factor or a marker of poor prognosis (<xref ref-type="bibr" rid="bib20">Fadaka et al., 2020</xref>; <xref ref-type="bibr" rid="bib79">Zhang et al., 2020</xref>; <xref ref-type="bibr" rid="bib77">Yuan et al., 2019</xref>; <xref ref-type="bibr" rid="bib40">Ma et al., 2015</xref>). Regardless, none of these studies consider the existence of distinct AURKA 3′UTR isoforms in their experimental design of targeting assessment. The <italic>hsa-let-7</italic> miRNA family comprises 11 closely related genes that map in chromosomal regions that are typically deleted in human tumors and, given their pathogenic downregulation in cancer, they are classified as tumor suppressors (<xref ref-type="bibr" rid="bib10">Bueno and Malumbres, 2011</xref>; <xref ref-type="bibr" rid="bib30">Johnson et al., 2007</xref>). Roles for <italic>hsa-let-7a</italic> in breast tumor growth and metastasis have been proposed (<xref ref-type="bibr" rid="bib66">Thammaiah and Jayaram, 2016</xref>; <xref ref-type="bibr" rid="bib60">Shi et al., 2020</xref>) and a correlation between <italic>hsa-let-7a</italic> expression and clinical variables has been detected in triple-negative breast cancer (TNBC) (<xref ref-type="bibr" rid="bib6">Avery-Kiejda et al., 2014</xref>; <xref ref-type="bibr" rid="bib68">Turashvili et al., 2018</xref>).</p><p>AURKA was classified within the TNBC subtype with the highest median index of 3′UTR shortening events (<xref ref-type="bibr" rid="bib71">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Akman et al., 2015</xref>), and also undergoes 3′UTR shortening in poor-prognosis patients of breast and lung cancer (<xref ref-type="bibr" rid="bib36">Lembo et al., 2012</xref>). Importantly, AURKA overexpression in TNBC represents a marker of early recurrence, poor prognosis, and shorter overall survival (<xref ref-type="bibr" rid="bib76">Xu et al., 2013</xref>; <xref ref-type="bibr" rid="bib29">Jalalirad et al., 2021</xref>). However, the correlation between AURKA PAS usage, protein expression, and pathological cell behavior has not been explored for this or other biological contexts, nor at the molecular level. In this study, we uncover a molecular mechanism leveraging the cellular ratio of APA isoforms and their different translational program during the cell cycle to control acquisition of AURKA oncogenic potential.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Increased short/long ratio of AURKA APA isoforms in TNBC</title><p>In a preliminary study using the APADetect in silico tool, we analyzed publicly available microarray data to identify changes in AURKA 3′UTR isoform abundance in tissues (<xref ref-type="bibr" rid="bib3">Akman et al., 2015</xref>). 520 comparable datasets for TNBC samples came from GSE31519 (<xref ref-type="bibr" rid="bib55">Rody et al., 2011</xref>) and 65 histologically normal epithelium and cancer-free prophylactic mastectomy patients were used: 32 from GSE20437 (<xref ref-type="bibr" rid="bib22">Graham et al., 2010</xref>), 12 from GSE9574 (<xref ref-type="bibr" rid="bib67">Tripathi et al., 2008</xref>), 7 from GSE3744 (<xref ref-type="bibr" rid="bib54">Richardson et al., 2006</xref>), 6 from GSE6883 (<xref ref-type="bibr" rid="bib39">Liu et al., 2007</xref>), 5 from GSE26910 (<xref ref-type="bibr" rid="bib53">Planche et al., 2011</xref>), and 3 from GSE21422 (<xref ref-type="bibr" rid="bib33">Kretschmer et al., 2011</xref>). The analysis revealed increased short/long ratio (SLR) of AURKA 3′UTR isoforms in TNBC compared to normal breast tissues (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Higher SLR was confirmed by RT-qPCR in multiple TNBC cell lines (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Furthermore, RT-qPCR analysis of normal and TNBC patient cDNAs from Origene Breast Cancer cDNA array IV (BCRT504) also showed higher AURKA SLR in TNBC samples compared to normal (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). In addition, the shortening of AURKA 3′UTR correlated with faster relapse times in TNBC patients (clinical data from <xref ref-type="bibr" rid="bib55">Rody et al., 2011</xref>; <xref ref-type="fig" rid="fig1">Figure 1E</xref>). These results therefore suggest a potential oncogenic role of AURKA APA in breast cancer worth further investigations.</p></sec><sec id="s2-2"><title>AURKA shows 3′UTR isoform-dependent protein expression</title><p>To probe AURKA APA isoform-dependent protein expression, we developed a single-cell expression sensor suitable for experiments in live cell. The construct independently expresses Venus and mCherry fluorescent proteins via a constitutive bi-directional promoter (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The coding sequence (CDS) of Venus is flanked by AURKA UTRs, whereas that of mCherry lacks regulatory regions and is therefore used to normalize for transfection efficiency. To test for APA-sensitive expression, we alternatively mutated the distal (d) or proximal (p) PAS on the reporter 3′UTR, to generate different 3′UTR isoforms (SHORT and LONG, respectively). Constructs lacking AURKA UTRs (Δ) and expressing AURKA wild-type UTRs (WT) were used as controls.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Aurora Kinase A (AURKA) shows 3′UTR isoform-dependent protein expression.</title><p>(<bold>A</bold>) Top: UTR-dependent protein expression reporters. Venus coding sequence (CDS) is flanked by AURKA 5′UTR and 3′UTR, WT or polyadenylation signal (PAS)-mutated. Bottom: representative snapshots of transfected U2OS cells. Scale bar 50 µm. (<bold>B</bold>) Mean and SEM of median Venus/mCherry mean fluorescence intensity (MFI) ratios from transfected U2OS cells from three biological replicates. n ≥ 129 cells per condition. Ordinary one-way ANOVA with Tukeys multiple-comparisons test. (<bold>C</bold>) 3′RACE of endogenous AURKA APA isoforms. (<bold>D</bold>) RT-qPCR of endogenous AURKA short/long ratio (SLR) in U2OS cells. Long isoform abundance plotted as fold change over total AURKA mRNA. 18S rRNA used as reference target. (<bold>E</bold>) Same as (<bold>B</bold>) but in MCF10A (left) and RPE1 (right) cells. n ≥ 55 cells per condition. Unpaired <italic>t</italic>-test. ns, not significant; *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw gel/blot images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87253-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Numerical data for graphs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-87253-fig2-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Validation of bidirectional reporter.</title><p>(<bold>A</bold>) R<sup>2</sup> (coefficient of determination) values to indicate goodness of fit of a simple linear regression between mCherry and Venus single-cell mean fluorescence intensity (MFI) values. Data relative to <xref ref-type="fig" rid="fig2">Figure 2B</xref>. (<bold>B</bold>) RT-qPCR of mCherry and Venus mRNAs from three RNA extracts of U2OS cells transfected with Δ reporter. Ct values are mean between three technical replicates of the amplification reaction. (<bold>C</bold>) Quantification of mCherry and Venus MFI from U2OS cells transfected with the Δ reporter and imaged at the indicated time points. Mean and SEM (n = 8 cells) shown at each time point. (<bold>D</bold>) Single-cell Venus/mCherry MFI values from U2OS<sup>CDK2</sup> cells transfected with Δ reporter grouped by intervals of CDK2 activity (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, right) and plotted as median and 95% CI. n = 43 cells analyzed. Kruskal–Wallis with Dunnett’s multiple-comparisons test; ns, not significant. (<bold>E</bold>) Mean and SEM of median Venus/mCherry MFI ratios from U2OS cells transfected with constructs containing long or short CDC6 3′UTR from three biological replicates. n ≥ 119 cells per condition. Unpaired <italic>t</italic>-test; ***p=0.0005.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Numerical data for graphs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-87253-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-fig2-figsupp1-v1.tif"/></fig></fig-group><p>We initially assessed the efficiency of the promoter bidirectionality. Correlation between Venus and mCherry expression was strongly maintained at the level of both fluorescence intensity (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) and mRNA abundance (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Promoter strength was, however, not equal in both directions since fewer copies of mCherry mRNA were transcribed compared to Venus mRNA (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), despite mCherry fluorescence intensity being generally higher than that of Venus (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>, see Δ). We further assessed that mRNA of both mCherry and Venus was stable over time (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, see Δ), and fluorescence of both proteins was stable over time and over different cell cycle stages (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and D</xref>). Considering the short maturation time and long half-life of both Venus and mCherry proteins (<xref ref-type="bibr" rid="bib59">Shaner et al., 2004</xref>; <xref ref-type="bibr" rid="bib46">Nagai et al., 2002</xref>), the assay allows to reliably measure effects of UTRs on reporter protein levels at any given time and regardless of cell cycle phases. As positive control of our assay, we recapitulated the higher protein expression from the short 3′UTR APA isoform of CDC6 mRNA, which has previously been observed (<xref ref-type="bibr" rid="bib2">Akman et al., 2012</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Aurora Kinase A (AURKA) alternative polyadenylation (APA) isoforms are translated with different efficiency.</title><p>(<bold>A</bold>, <bold>B</bold>) RT-qPCR of reporter mRNAs abundance (<bold>A</bold>) and decay rate (<bold>B</bold>) from transfected U2OS cells. mCherry mRNA used as reference target. Ordinary one-way ANOVA with Tukey’s multiple-comparisons test; ns, not significant. (<bold>C</bold>) Decay rate of endogenous AURKA mRNA as in (<bold>B</bold>). 18S rRNA used as reference target. Abundance of long isoform plotted as fold change over total AURKA mRNA. (<bold>D</bold>) Design of the nascent chain immunoprecipitation (NC IP) reporters and assay. (<bold>E</bold>) Mean and SEM of median FlagVenus/mCherry mean fluorescence intensity (MFI) ratios from transfected U2OS cells from two biological replicates. n ≥ 160 cells per condition. Unpaired <italic>t</italic>-test; **p&lt;0.005. (<bold>F</bold>), (<bold>G</bold>) Immunoblots of NC IP fractions using Δ (<bold>F</bold>) or Flag-Δ (<bold>G</bold>) reporter. mCherry used as negative control. (<bold>H</bold>) RT-qPCR of eluted reporter mRNAs. Results representative of three biological replicates.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Numerical data for graphs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-87253-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Raw gel/blot images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87253-fig3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-fig3-v1.tif"/></fig><p>Addition of AURKA UTRs to Venus CDS significantly increased protein expression (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>), likely due to the role of 5′UTR in facilitating translation (<xref ref-type="bibr" rid="bib28">Hinnebusch et al., 2016</xref>). We found that the SHORT reporter generates significantly more protein compared to the LONG (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Moreover, similar protein expression levels from the WT and LONG reporters suggest that AURKA WT 3′UTR is processed with a preference for dPAS in U2OS cells. Accordingly, we could detect both endogenous AURKA APA isoforms in U2OS cells by 3′RACE (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) and confirmed by RT-qPCR that AURKA long isoform is prevalent (~60% of total AURKA mRNA) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The different SLR observed between U2OS cells, normal breast tissues, and TNBC cell lines and tissues (<xref ref-type="fig" rid="fig1">Figure 1B–D</xref>) indicates that AURKA 3′UTR isoform prevalence is dependent on cell type. In addition, the quantitative difference in reporter protein expression by the isoforms also varied among cell types, suggesting cell-specific regulation (<xref ref-type="fig" rid="fig2">Figure 2B and E</xref>, SHORT vs. LONG). In sum, these results provide evidence for the first time of a role for APA in controlling AURKA protein expression.</p></sec><sec id="s2-3"><title>AURKA APA isoforms are translated with different efficiency</title><p>We next investigated the basis of the different protein expression between AURKA APA isoforms. Following transfection of U2OS cells with the constructs in <xref ref-type="fig" rid="fig2">Figure 2A</xref>, we first quantified the abundance of reporter mRNA isoforms (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We then assessed the isoforms decay rate by quantifying reporter mRNAs at multiple time points following arrest of transcription by actinomycin D (ActD) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We observed that while Venus mRNA lacking UTRs was highly stable, reporter mRNA levels decreased at faster rate when carrying UTRs (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), indicating that the assay reports on UTR-dependent effects on mRNA stability. Both the abundance and stability of the SHORT and LONG reporter isoforms were similar (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). We additionally found that the two endogenous AURKA 3′UTR isoforms also have similar decay rates, albeit decaying at a higher rate compared to the reporter mRNAs (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), suggesting that features present in AURKA CDS might influence mRNA stability (<xref ref-type="bibr" rid="bib47">Narula et al., 2019</xref>).</p><p>Because the reporter APA isoforms share similar abundance and stability, we wondered whether they undergo different translational regulation instead. To this aim, we adapted a biochemical translation efficiency (TE) assay from <xref ref-type="bibr" rid="bib73">Williams et al., 2022</xref>, which required addition of a 3XFlag tag to the N-terminus of Venus (FlagVenus) in our reporter constructs, and called this nascent chain immunoprecipitation (NC IP) assay (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). We first assessed that addition of the 3XFlag tag did not alter Venus expression (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). In our NC IP assay, anti-Flag beads were used to immunoprecipitate nascent FlagVenus chains from ribosomes stalled by treatment with cycloheximide (CHX). Ribosome-mRNA complexes were eluted from the IP-immobilized nascent chains using puromycin, which causes release of nascent chains from ribosomes (<xref ref-type="bibr" rid="bib7">Aviner, 2020</xref>); RNA was then purified from the elution fraction and quantified by RT-qPCR to provide a measure of the amount of reporter mRNA undergoing translation. All fractions were then blotted for FlagVenus and mCherry (negative control) proteins to monitor their presence at different steps of the experiment. As expected, elution with puromycin retained FlagVenus on the beads, whereas mCherry, as well as untagged Venus, are lost in the flow-through (<xref ref-type="fig" rid="fig3">Figure 3G, left, and F</xref>). No reporter mRNA could be detected in the elution fraction when untagged Venus was used (data not shown). Alternatively, purified 3XFlag peptide was used to elute the nascent chain-ribosome-mRNA complexes from the beads following IP (<xref ref-type="fig" rid="fig3">Figure 3G</xref>, right). RT-qPCR quantification of the FlagVenus nascent chain-cognate reporter mRNAs revealed about twice more copies of Flag-S mRNA compared to Flag-L mRNA, regardless of the elution method (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). This indicates that Flag-S mRNA is translated with higher efficiency than Flag-L mRNA. These results show that APA controls AURKA protein expression mainly via differential translational regulation of the 3′UTR isoforms.</p></sec><sec id="s2-4"><title>Translation rate of AURKA APA isoforms follows different cell cycle periodicity</title><p>Given the known cell cycle-dependent expression of AURKA (<xref ref-type="bibr" rid="bib12">Cacioppo and Lindon, 2022</xref>), we tested whether differential translational efficiency of AURKA mRNA isoforms might contribute to this regulation. To avoid perturbation of translation provoked by classical cell cycle synchronization methods (<xref ref-type="bibr" rid="bib4">Anda and Grallert, 2019</xref>), we used a live-cell fluorescence-based translation rate measurement assay in conjunction with a CDK2 activity sensor (<xref ref-type="bibr" rid="bib62">Spencer et al., 2013</xref>) for in silico cell cycle synchronization. We developed our assay of ‘translation rate imaging by rate of protein stabilization’ (TRIPS) based on a previously introduced reporter system (<xref ref-type="bibr" rid="bib27">Han et al., 2014</xref>; <xref ref-type="bibr" rid="bib64">Tanenbaum et al., 2015</xref>). Our bidirectional promoter construct was modified to express superfolder GFP (sfGFP) fused to a mutated <italic>Echerichia coli</italic> dihydrofolate reductase (DHFR-Y100I) destabilizer domain (DHFR-sfGFP), which is continuously degraded unless the stabilizer molecule trimethoprim (TMP) is added. Addition of TMP leads to an increase of sfGFP signal over time and, given the sfGFP short maturation time (<xref ref-type="bibr" rid="bib51">Pédelacq et al., 2006</xref>), the accumulation rate of sfGFP reflects DHFR-sfGFP protein synthesis rate (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, left<italic>,</italic> <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). The ratio of the median of single-cell mCherry-normalized sfGFP signals at 2 hr to that at 0 hr of TMP treatment was therefore used as read-out for bulk translation rate. In accordance with our assay being designed to measure translation rate, sfGFP signal could not increase under TMP treatment in the presence of translation inhibitor CHX (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). We also ensured that the increase in sfGFP signal was TMP-dependent (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>) and that TMP treatment affected neither mCherry expression (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>) nor DHFR-sfGFP mRNA abundance (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). To probe translation rate at different cell cycle phases, we used the CDK2 activity sensor (<xref ref-type="bibr" rid="bib62">Spencer et al., 2013</xref>) stably expressed in our U2OS cell line (U2OS<sup>CDK2</sup>) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) and called this assay ‘cell cycle-dependent TRIPS’ (C-TRIPS) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, right).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Translation rate of Aurora Kinase A (AURKA) alternative polyadenylation (APA) isoforms follows different cell cycle periodicity.</title><p>(<bold>A</bold>) Design of the translation rate imaging by rate of protein stabilization (TRIPS) reporters and assay (left) and CDK2 activity sensor (right). (<bold>B</bold>) Mean and SEM of median sfGFP/mCherry mean fluorescence intensity (MFI) ratios from U2OS cells transfected with TRIPS-Δ and imaged at 0 hr and 2 hr of 50 µM trimethoprim (TMP) treatment, with or without 0.1 mg/ml cycloheximide (CHX), from three biological replicates. Baseline at 0 hr. n ≥ 55 cells per condition. (<bold>C</bold>) RT-qPCR of sfGFP mRNA from U2OS cells transfected with TRIPS-Δ, at 0 hr and 2 hr of 50 µM TMP treatment. mCherry mRNA used as reference target. RNA extracts at 0 hr of treatment used as reference sample. (<bold>D</bold>) TRIPS (left) and C-TRIPS (right) assays in transfected U2OS<sup>CDK2</sup> cells. n ≥ 200 cells per condition. Left: mean and SEM from three biological replicates. Right: median and 95% CI of pooled data from left. Kruskal–Wallis with Dunnett’s multiple-comparisons test. (<bold>E</bold>) RT-qPCR of endogenous AURKA mRNA in U2OS cells. 18S rRNA used as reference target. Baseline at G<sub>1</sub>/S. (<bold>F</bold>) Endogenous AURKA long isoform as in (<bold>E</bold>) plotted as percentage of total AURKA mRNA. (<bold>D</bold>) Left, (<bold>E</bold>, <bold>F</bold>) Ordinary one-way ANOVA with Tukey’s multiple-comparisons test. ns, not significant; *p&lt;0.05; **p&lt;0.01; ***p&lt;0.0005; ****p&lt;0.0001.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Numerical data for graphs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-87253-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Validation of TRIPS assay.</title><p>(<bold>A</bold>) Left: representative U2OS cells transfected with TRIPS-S and imaged at 0 hr and 2 hr of 50 µM trimethoprim (TMP) treatment. Right: representative U2OS<sup>CDK2</sup> cells. (<bold>B</bold>) TRIPS assay performed in U2OS cells transfected with TRIPS-Δ and treated with DMSO for 2 hr. Mean and SEM of median sfGFP/mCherry ratios from two biological replicates, with baseline at 0 hr. n = 95 cells analyzed. (<bold>C</bold>) Graph using data from <xref ref-type="fig" rid="fig4">Figure 4D</xref> showing mean fluorescence intensity (MFI) of mCherry and sfGFP at 0 hr and 2 hr of TMP treatment. Mean and SEM of median MFI values from three biological replicates. (<bold>D</bold>) TRIPS assay performed in transfected U2OS cells and imaged at 0 hr and 2 hr of 50 µM TMP treatment. Ratios between the median of single-cell sfGFP/mCherry ratios at 2 hr and that at 0 hr of TMP treatment were calculated for two biological replicates and are shown as mean and s.e.mSEM. n ≥ 343 cells analyzed per condition. (<bold>B–D</bold>) Unpaired <italic>t</italic>-test. ns, not significant; *p&lt;0.05.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Numerical data for graphs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-87253-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-fig4-figsupp1-v1.tif"/></fig></fig-group><p>To test the translation rate of the individual AURKA APA isoforms, we flanked DHFR-sfGFP CDS with AURKA PAS-mutated UTRs (TRIPS-L, TRIPS-S) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, left). We found that our TRIPS assay could recapitulate the difference in translation efficiency of the isoforms previously observed (<xref ref-type="fig" rid="fig3">Figures 3H</xref> and <xref ref-type="fig" rid="fig4">4D</xref>, left). Importantly, expression of the CDK2 activity sensor did not affect cellular translation as the different translation rate of AURKA 3′UTR isoforms could be reproduced in U2OS cells lacking the sensor (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). Following measurements of bulk translation rates (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, left), we then binned single-cell translation rate values into three intervals of CDK2 activity (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, right). Results of our C-TRIPS assay revealed that, while TRIPS-Δ is translated constantly during the cell cycle, translation rate of TRIPS-L is regulated in the cell cycle. This isoform showed lower translation rate in G<sub>1</sub> and S and an enhanced rate at G<sub>2</sub>, consistent with the increase in both AURKA mRNA and protein levels that occurs in preparation for mitosis (<xref ref-type="bibr" rid="bib12">Cacioppo and Lindon, 2022</xref>). By contrast, TRIPS-S was translated constantly through the cell cycle and at a maximal rate already in G<sub>1</sub> (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, right), indicating that this isoform is insensitive to cell cycle regulation of AURKA translation rate.</p><p>Furthermore, we quantified abundance of endogenous AURKA APA isoforms at different stages of the cell cycle by performing RT-qPCR following synchronization in G<sub>1</sub>/S, G<sub>2</sub>, or M phases (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). The expected changes in AURKA mRNA abundance following each treatment represent a positive control for the synchronization. However, abundance of the long isoform changed quite concomitantly with changes in total AURKA mRNA levels (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). This suggests that the same ratio of 3′UTR isoforms is rather maintained throughout the cell cycle and that AURKA APA is not cell cycle regulated.</p><p>These results not only provide strong, independent validation of our finding that elements present in 5′ and 3′ UTR of AURKA enable translational activation but additionally indicate that elements present on the long 3′UTR might account for its different pattern of translation during interphase as lack of these on the short 3′UTR allow escape from cell cycle phase-dependent translation.</p></sec><sec id="s2-5"><title>Translational periodicity of long 3′UTR isoform is regulated by <italic>hsa-let-7a</italic> miRNA</title><p>Among known post-transcriptional regulators, miRNAs are widely recognized as molecular regulators of both mRNA stability and translation (<xref ref-type="bibr" rid="bib31">Jonas and Izaurralde, 2015</xref>). We interrogated miRDB (<ext-link ext-link-type="uri" xlink:href="https://mirdb.org/">https://mirdb.org/</ext-link>) (<xref ref-type="bibr" rid="bib13">Chen and Wang, 2020</xref>) to search for miRNAs that could be involved in the differential regulation of the two AURKA mRNA isoforms and selected <italic>hsa-let-7a</italic> miRNA (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) given its widely established tumor-suppressor role of in TNBC. We assessed the <italic>hsa-let-7a</italic> targeting of AURKA 3′UTR by co-transfecting our AURKA UTR-dependent protein expression reporters (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) with <italic>hsa-let-7a</italic> or a negative control miRNA that does not have any target in the human genome. As positive control of the assay, we cloned Myeloid Zinc Finger1 (MZF1) 3′UTR downstream Venus CDS in our Δ reporter and could reproduce the previously reported targeting of MZF1 3′UTR by <italic>hsa-let-7a</italic> (<xref ref-type="bibr" rid="bib69">Tvingsholm et al., 2018</xref>; <xref ref-type="fig" rid="fig5">Figure 5B</xref>). Protein expression from the LONG reporter mRNA was reduced by <italic>hsa-let-7a</italic>, whereas that from the SHORT mRNA and from a LONG mRNA that lacks the <italic>hsa-let-7a</italic> binding site (Δlet7a) was not (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Also, the loss of <italic>hsa-let-7a</italic> targeting was sufficient to increase protein expression from the LONG reporter mRNA (compare LONG + NC vs. Δlet7a + NC). To confirm that altered expression was due to the lack of <italic>hsa-let-7a</italic> targeting and not an effect of the mutation itself, we also observed an increase in protein expression when we co-transfected our LONG reporter and an inhibitor of <italic>hsa-let-7a</italic> (<italic>anti-let7a</italic>) (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Translational periodicity of long 3′UTR isoform is regulated by <italic>hsa-let-7a</italic> miRNA.</title><p>(<bold>A</bold>) Complementarity of <italic>hsa-let-7a</italic> binding to Aurora Kinase A (AURKA) 3′UTR. (<bold>B</bold>) Mean and SEM of median Venus/mCherry mean fluorescence intensity (MFI) ratios from U2OS cells co-transfected with 250 nM <italic>hsa-let-7a</italic> or a negative control (NC) miRNA from three biological replicates. n ≥ 182 cells per condition. Unpaired <italic>t</italic>-test. (<bold>C</bold>) Same as (<bold>B</bold>) but co-transfecting 300 nM <italic>anti-let-7a</italic> or NC. n ≥ 94 cells per condition. Unpaired <italic>t</italic>-test. (<bold>D</bold>) RT-qPCR of reporter mRNAs abundance from U2OS cells transfected as (<bold>B</bold>), at 8 hr of 10 μg/ml ActD. mCherry mRNA used as reference target. Ordinary one-way ANOVA with Tukey’s multiple-comparisons test. (<bold>E</bold>) Translation rate imaging by rate of protein stabilization (TRIPS) (left) and C-TRIPS (right) assays in transfected U2OS<sup>CDK2</sup> cells. n ≥ 162 cells per condition Left: mean and SEM from three biological replicates. Ordinary one-way ANOVA with Dunnett’s multiple-comparisons test vs. NC. Right<italic>:</italic> median and 95% CI of pooled data from left. Kruskal–Wallis with Dunnett’s multiple-comparisons test vs. NC of the respective phase. ns, not significant; *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Numerical data for graphs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-87253-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-fig5-v1.tif"/></fig><p>In order to assess the role of <italic>hsa-let-7a</italic> in controlling decay rate of the target mRNA, we next co-transfected our Venus reporters and either <italic>hsa-let-7a</italic> or negative control miRNA and quantified reporter mRNA abundance after 8 hr of ActD treatment. We found that stability of the LONG reporter mRNA was significantly reduced by <italic>hsa-let-7a</italic>, whereas that of the SHORT reporter mRNA was unaltered. Additionally, mutation of the <italic>hsa-let-7a</italic> binding site slightly increased reporter mRNA stability (compare LONG + NC vs. Δlet7a + NC) (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p><p>We then performed our C-TRIPS assay co-transfecting the TRIPS-L reporter and <italic>hsa-let-7a</italic> or control miRNA and found that <italic>hsa-let-7a</italic> reduced both bulk translation rate (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, left) and translation rate at all interphase stages (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, right) of the long 3′UTR. Furthermore, we asked whether loss of <italic>hsa-let-7a</italic> targeting is sufficient to cause loss of translational regulation of the long isoform during the cell cycle. For this, we performed the C-TRIPS assay using a TRIPS-L reporter with mutations in the <italic>hsa-let-7a</italic> binding site (TRIPS-Δlet7a) or, alternatively, co-transfecting the TRIPS-L reporter and the <italic>hsa-let-7a</italic> inhibitor <italic>anti-let7a</italic>. Interestingly, in both cases, loss of <italic>hsa-let-7a</italic> targeting only increased translation rate in G<sub>1</sub> and S, but not G<sub>2</sub> (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, right), suggesting that the targeting in G<sub>2</sub> is not likely to occur unless in conditions of excess <italic>hsa-let-7a</italic>.</p><p>In conclusion, our results show that <italic>hsa-let-7a</italic> only silences AURKA long 3′UTR isoform by both promoting mRNA degradation and reducing translation rate, and that <italic>hsa-let-7a</italic> targeting is responsible for the cell cycle-dependent translational regulation of AURKA long 3′UTR isoform.</p></sec><sec id="s2-6"><title>Increased AURKA short/long ratio is sufficient to disrupt cell behavior</title><p>Having established that APA plays a role in regulating AURKA expression, we tested the idea that AURKA APA directly contributes to cancer cell behavior by performing genome editing to alter AURKA APA in wild-type U2OS cells. We used Cas9<sup>D10A</sup>-mediated double-nicking strategy and mutated the endogenous dPAS on <italic>AURKA</italic> 3′UTR with the aim of silencing expression of AURKA long 3′UTR isoform (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Two mutant clones with disrupted dPAS site were obtained (ΔdPAS#1, ΔdPAS#2) (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>) and were used for subsequent functional analyses. Qualitative assessment of AURKA 3′UTR isoforms ratio in these clones by 3′RACE found the long 3′UTR isoform to be undetectable in the mutated cell lines (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), indicating that the genetic editing successfully prevents usage of the dPAS site for cleavage and polyadenylation.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Increased Aurora Kinase A (AURKA) short/long ratio is sufficient to disrupt cell behavior.</title><p>(<bold>A</bold>) Design of CRISPR editing. Nucleotide substitutions in red. (<bold>B</bold>) 3′RACE of endogenous AURKA alternative polyadenylation (APA) isoforms. (<bold>C</bold>), (<bold>D</bold>) Western blot after G<sub>1</sub>/S enrichment (<bold>C</bold>) and with or without 6 hr treatment with 0.1 mg/ml cycloheximide (CHX) (<bold>D</bold>). Blots representative of three biological replicates. (<bold>E</bold>) CCK8 assay. A nonparental WT U2OS cell line used as negative control. Ordinary one-way ANOVA with Dunnett’s multiple-comparisons test vs. WT; **p&lt;0.005; ***p&lt;0.001. (<bold>F</bold>) Left: representative images of cells grown in soft agar. Right: mean number of clones and SEM of three biological replicates. (<bold>G</bold>) Measurement of migration rate. (<bold>F</bold>, <bold>G</bold>) Ordinary one-way ANOVA with Dunnett’s multiple-comparisons test vs. WT; *p&lt;0.05; **p&lt;0.01.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw gel/blot images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87253-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Numerical data for graphs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-87253-fig6-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Validation of mutated cell lines.</title><p>(<bold>A</bold>) Sanger sequencing validation of the mutated dPAS element in two cell lines. (<bold>B</bold>) Western blot showing similar Aurora Kinase A (AURKA) protein expression in unsynchronized WT or U2OS cell lines that were not mutated following CRISPR editing (#1, #2).</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Raw gel/blot images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87253-fig6-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-fig6-figsupp1-v1.tif"/></fig></fig-group><p>We then examined expression of AURKA in the mutated cell lines by immunoblot of extracts from cell populations enriched for the G<sub>1</sub>/S phase of the cell cycle, where AURKA expression is the lowest in unmodified cells. We observed AURKA was expressed at higher levels in ΔdPAS#1 and ΔdPAS#2 cells compared to WT cells (<xref ref-type="fig" rid="fig6">Figure 6C</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). AURKA expression in G<sub>1</sub>/S was reduced in the mutated cell lines when treated with CHX, indicating that translation of the short isoform is active in this phase (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Because AURKA overexpression is a common feature of cancer, we interrogated the mutated cell lines for changes in cancer-relevant behavior. Consistent with a role of AURKA overexpression in accelerating the cell cycle and favoring cell proliferation, we found a higher rate of proliferation of ΔdPAS#1 and ΔdPAS#2 cells compared to WT cells using the CCK8 assay to measure metabolic activity (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Additionally, we assessed the ability of anchorage-independent growth, which closely correlates with tumorigenicity in animal models by growing cells in soft agar. ΔdPAS#1 and ΔdPAS#2 cells resulted more capable to survive and grow in the absence of anchorage to their neighboring cells compared to WT cells (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). AURKA also regulates organization of microtubules required for cellular migration and also enhances migration of tumor cells through several pathways. For example, AURKA activates the Cofilin-F-Actin pathway leading to breast cancer metastases (<xref ref-type="bibr" rid="bib72">Willems et al., 2018</xref>). We were therefore prompted to assess the motility of ΔdPAS#1 and ΔdPAS#2 cells in a 2D cell migration assay. Our result shows a higher rate of migration of ΔdPAS#1 and ΔdPAS#2 cells compared to WT cells (<xref ref-type="fig" rid="fig6">Figure 6G</xref>).</p><p>In summary, our results show that AURKA overexpression caused by a disruption in the SLR of APA isoforms in favor of the short isoform contributes to cancer-like cell behavior.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we describe for the first time a molecular mechanism involving the dysregulation of APA and the differential targeting of AURKA APA isoforms by <italic>hsa-let-7a</italic>, a tumor suppressor miRNA, that is sufficient for the oncogenic activation of AURKA at the post-transcriptional level. We also shed light on the cell cycle-dependent regulation of AURKA translation and introduce novel and improved methods for measurements of post-transcriptional gene expression of individual mRNAs of interest.</p><p>As a consequence of tandem 3′UTR APA, a short and a long 3′UTR isoform are generated for AURKA mRNA. The SLR of these isoforms is cell-type defined and is not dependent on the cell cycle, indicating that cell-type-specific/cell cycle-independent factors are involved in establishing the SLR. This is unexpected given that periodic regulation of APA may be a characteristic of many cell cycle genes (<xref ref-type="bibr" rid="bib17">Dominguez et al., 2016</xref>). Because protein expression differs from the two isoforms, AURKA SLR is a crucial element defining AURKA expression levels. Ours and other studies detected increased SLR of AURKA APA isoforms in TNBC and found this correlates with worse disease-free survival (<xref ref-type="bibr" rid="bib71">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Akman et al., 2015</xref>). Here, we reveal insights into the molecular basis for the correlation by showing that the increased and cell cycle-independent translation rate of the short isoform can lead to marked overexpression of AURKA in interphase. Our results support the hypothesis that deregulation of expression by disruption of APA is sufficient to drive AURKA oncogenic properties, such as promoting increased proliferation and migration rate. Whether this is also sufficient to drive cancer-cell transformation remains to be explored. It has been known for many years that overexpression of AURKA induces mitotic defects, aneuploidy, as well as acceleration of the cell cycle, epithelial-to-mesenchymal transition and migration (<xref ref-type="bibr" rid="bib72">Willems et al., 2018</xref>; <xref ref-type="bibr" rid="bib80">Zhou et al., 1998</xref>), whilst the cellular background for AURKA’s transforming potential is also of importance (<xref ref-type="bibr" rid="bib5">Asteriti et al., 2010</xref>). Nonetheless, the significance of AURKA overexpression specifically in G<sub>1</sub> for the exertion of potential oncogenic functions in this phase represents an emerging field of research (<xref ref-type="bibr" rid="bib48">Naso et al., 2021</xref>; <xref ref-type="bibr" rid="bib1">Abdelbaki et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">Bertolin and Tramier, 2020</xref>). It is possible that normal AURKA functions are exerted at low levels of expression in G<sub>1</sub> become oncogenic at high levels of expression. This would not be surprising given how the roles played by AURKA in G<sub>1</sub> revolve around regulation of transcription, mitochondria fitness, and cellular metabolism.</p><p>Our work does not research the cause of the disrupted APA in TNBC. This could be concomitant to a global 3′UTR shortening, for example, due to altered expression in cancer of C/P factors (<xref ref-type="bibr" rid="bib26">Gruber and Zavolan, 2019</xref>; <xref ref-type="bibr" rid="bib71">Wang et al., 2020</xref>), or of their regulators (<xref ref-type="bibr" rid="bib52">Pieraccioli et al., 2022</xref>), or even altered RNA Pol II elongation dynamics (<xref ref-type="bibr" rid="bib44">Mitschka and Mayr, 2022</xref>). However, these phenomena have not been extensively explored in TNBC (<xref ref-type="bibr" rid="bib43">Miles et al., 2016</xref>). Alternatively, disrupted APA could represent an AURKA gene-specific phenomenon due to the presence of single-nucleotide polymorphisms (SNPs) on the 3′UTR either on the C/P site or in proximity that could affect PAS choice by the C/P machinery. Finally, an mRNA-dependent mechanism whereby the short 3′UTR isoform itself regulates AURKA protein function or localization throughout or at specific phases of the cell cycle, licensing oncogenic advantage, should not be excluded (<xref ref-type="bibr" rid="bib44">Mitschka and Mayr, 2022</xref>).</p><p>The periodicity of AURKA expression is an important requirement for correct progression through the cell cycle. For example, ubiquitin-mediated proteolysis is a critical pathway for irreversible AURKA inactivation, which must occur for ordered transition to interphase following mitosis (<xref ref-type="bibr" rid="bib1">Abdelbaki et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Lindon et al., 2015</xref>). One important but unanswered question is whether and to what extent translation regulation accounts for the increase and decrease of AURKA expression during the cell cycle. Implementation of our TRIPS assay, which measures protein synthesis rate independent of changes in mRNA abundance, allowed detection of active regulatory mechanisms of translation occurring at different cell cycle phases. This new evidence integrates well with the notion that transcriptional, post-transcriptional, and post-translational mechanisms all combine to provide <italic>AURKA</italic> gene with a characteristic pattern of expression (<xref ref-type="bibr" rid="bib12">Cacioppo and Lindon, 2022</xref>). Our work shows that translation of AURKA is regulated by <italic>hsa-let-7a</italic> miRNA. Because we could still detect active protein synthesis from the long isoform under <italic>hsa-let-7a</italic> overexpression using our TRIPS assay, and we could also immunoprecipitate tagged nascent chains from the long isoform in U2OS cells, where <italic>hsa-let-7a</italic> is expressed, it is unlikely that <italic>hsa-let-7a</italic> blocks translation at the level of initiation, but it rather slows down the rate of translation elongation. This is in accordance with a study showing that <italic>hsa-let-7a</italic> co-sediments with actively translating polyribosomes (<xref ref-type="bibr" rid="bib49">Nottrott et al., 2006</xref>), a generally proved mechanism of miRNA action (<xref ref-type="bibr" rid="bib65">Tat et al., 2016</xref>). In addition, because we observed that <italic>hsa-let-7a</italic> can also control the decay rate of the long isoform, it is possible that a reduction in translation elongation rate may be required to mediate degradation of the mRNA (<xref ref-type="bibr" rid="bib9">Biasini et al., 2021</xref>). We also show that the differential <italic>hsa-let-7a</italic> targeting through the cell cycle is a mechanism responsible for AURKA periodic translational control. Based on evidence from our C-TRIPS assays to assess the temporal <italic>hsa-let-7a</italic> targeting of the long isoform at different phases of the cell cycle, and on the published evidence that <italic>hsa-let-7a</italic> levels are constant during the cell cycle of human cancer cells as well as untransformed fibroblasts (<xref ref-type="bibr" rid="bib24">Grolmusz et al., 2016</xref>), we propose that (i) <italic>hsa-let-7a</italic> targeting is productive in G<sub>1</sub> and S, and is therefore responsible for the low AURKA translation rate in these phases; and (ii) the targeting is not occurring in G<sub>2</sub> phase, except in excess of <italic>hsa-let-7a</italic>, possibly because <italic>hsa-let-7a</italic> overexpression saturates sequestering factors that prevent its binding to the long isoform. Further investigations will be required to understand this mechanism in more detail.</p><p>The characterization of gene-specific post-transcriptional dynamics is desirable for a complete understanding of gene expression regulation. Here, we have developed transient single-cell and biochemical assays to rapidly study mRNA-specific gene expression in a way that measures post-transcriptional events exclusively. Importantly, the assays can be used to test the effect of regulators such as therapeutic miRNAs or drugs on protein expression, mRNA processing, and translation of selected genes.</p><p>In conclusion, our study reveals a strong cooperation between APA and miRNA targeting in controlling gene expression dynamics of AURKA and its oncogenic potential. It also provides a workflow to assess the role of mRNA-specific post-transcriptional processing and regulators. Our work additionally highlights a molecular mechanism that could represent an actionable target of RNA-based therapeutics.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>In silico analysis of APA in TNBC</title><p>Publicly available CEL files and associated metadata of microarray results were downloaded from NCBI Gene Expression Omnibus (GEO) repository. APADetect tool (<xref ref-type="bibr" rid="bib3">Akman et al., 2015</xref>) was used to detect and quantify APA events in TNBC patients and normal breast tissue. CEL files of Human Genome U133A (HGU133A, GPL96) and U133 Plus 2.0 Arrays (HGU133Plus2, GPL570) were analyzed to identify intensities of probes that were grouped based on poly(A) site locations extracted from PolyA_DB (<xref ref-type="bibr" rid="bib78">Zhang et al., 2005</xref>). Mean signal intensities of proximal and distal probe sets for AURKA were calculated and used as indicators of ‘short’ and ‘long’ AURKA 3′UTR isoforms’ abundance. The ratio of proximal probe set mean (S) to the distal probe set (L) is defined as short to long ratio (SLR). SLR values were subjected to significance analysis of microarrays (SAM), as implemented by the TM4 Multiple Array Viewer tool (<xref ref-type="bibr" rid="bib56">Saeed et al., 2003</xref>), for statistical significance after log normalization.</p></sec><sec id="s4-2"><title>Molecular cloning</title><p>The following UTR sequences were obtained by gene synthesis (Genewiz from Azenta Life Sciences, European Genomics Headquarters, Germany): AURKA WT 5′UTR and 3′UTR (769 bp) (NM_003600.4), MZF1 3′UTR (NM_003422.3), AURKA individual PAS-mutated 3′UTRs (AATAAA&gt;AATCCC). CDC6 3′UTRs were from <xref ref-type="bibr" rid="bib2">Akman et al., 2012</xref>. For Δ reporter, mCherry and Venus ORFs were inserted into the MCSs of <italic>pBI-CMV1</italic> (631630, Clontech, TakaraBio). <italic>WT</italic>, <italic>SHORT</italic> and <italic>LONG</italic> reporters were generated by assembly (NEBuilder HiFi DNA Assembly Cloning Kit, E5520S, NEB) of AURKA 5′UTR, Venus ORF and AURKA wt, short (dPAS-mutated) or long (pPAS-mutated) 3′UTR, and insertion into <italic>pBI-CMV1-mCherry. CDC6_L</italic>, <italic>CDC6_S</italic>, and <italic>MZF1</italic> reporters were generated by insertion of CDC6 long or short 3′UTR, and MZF1 3′UTR downstream Venus CDS in Δ reporter. <italic>LONG-Δlet7a</italic> was generated by site-directed mutagenesis of <italic>LONG</italic> reporter with the following forward and reverse primers: 5′-<named-content content-type="sequence">CACGCACCATTTAGGGATTTGCTTG</named-content>-3′ and 5′<named-content content-type="sequence">AGCACGTGTTCCTATTTTTCACACTC</named-content>-3′. <italic>Flag-Δ</italic> was generated by insertion of 3XFlag-Venus ORF into <italic>pBI-CMV1-mCherry. Flag-S</italic> and <italic>Flag-L</italic> reporters were generated by assembly of AURKA 5′UTR, 3XFlag-Venus ORF and AURKA short (dPAS-mutated) or long (pPAS-mutated) 3′UTR, and insertion into <italic>pBI-CMV1-mCherry</italic>. For <italic>TRIPS</italic> reporters, the DHFR-sfGFP ORF was PCR amplified from <italic>pHR-DHFRY100I-sfGFP-NLS-P2A-NLS-mCherry-P2A_Emi1 5' and 3'UTR</italic> plasmid, a gift from Ron Vale (Addgene plasmid #67930), and inserted into <italic>pBI-CMV1-mCherry</italic> (<italic>TRIPS-Δ</italic>) or assembled with AURKA 5′UTR and AURKA wt 3′UTR (<italic>TRIPS-WT</italic>), short 3′UTR (<italic>TRIPS-S</italic>), or long 3′UTR (<italic>TRIPS-L</italic>) before insertion. <italic>TRIPS-Δlet7a</italic> was generated by site-directed mutagenesis of <italic>TRIPS-L</italic> reporter with the primers above. NEB 5-alpha Competent <italic>E. coli</italic> (High Efficiency) (C2987I, NEB) was used.</p></sec><sec id="s4-3"><title>Cell lines and drug treatments</title><p>Human U2OS, U2OS<sup>CDK2</sup>, BT20, HCC1143, HCC1937, MDA-MB-157, MDA-MB-231, and MDA-MB-468 cell lines were cultured in DMEM (41966029, Thermo Fisher) supplemented with 10% FBS (F9665, Sigma), 200 μM GlutaMAX-1 (35050061, Thermo Fisher), 100 U/ml penicillin (15140122, Thermo Fisher), 100 μg/ml streptomycin (15140122, Thermo Fisher), and 250 ng/ml fungizone (15290026, Thermo Fisher) at 37°C with 5% CO<sub>2</sub>. U2OS<sup>CDK2</sup> cells cultures were supplemented with 500 µg/ml G-418 (G8168, Sigma). Human MCF10A were cultured in filtered DMEM-F12 (31331093, Thermo Fisher) supplemented with 10% FBS, 20 ng/ml EGF (AF-100-15, Peprotech), 0.5 mg/ml hydrocortisone (H4001, Sigma), 100 ng/ml cholera toxin (C8052, Sigma), 10 µg/ml insulin (I9278, Sigma), 100 U/ml penicillin, 100 μg/ml streptomycin, and 250 ng/ml fungizone at 37°C with 5% CO<sub>2</sub>. Human RPE1 cells were cultured as previously described (<xref ref-type="bibr" rid="bib23">Grant et al., 2018</xref>). Breast cancer cell lines were purchased from DSMZ (Germany) or ATCC (USA) with authentication certificates including STR profiling; all cell lines used in the study were free of mycoplasma contamination. Cell populations were enriched for G<sub>1</sub>/S phase by incubating with 2.5 mM thymidine (T1895, Sigma) for 24 hr, for G<sub>2</sub> phase by incubating with 10 μM RO3306 (4181, Tocris Bioscience) for 16 hr, for M phase by incubating with 10 μM S-trityl l-cysteine (STLC) (2191/50, Tocris Bioscience) for 16 hr, and mitotic cells were then collected by shake-off. CHX (239763, Sigma), TMP (92131, Sigma), and DMSO (sc-358801, Insight Biotech) were used as indicated in the figure legends.</p></sec><sec id="s4-4"><title>Transfections</title><p>U2OS and RPE1 cells (5 × 10<sup>6</sup>) were electroporated (MPK5000, Neon Transfection System, Invitrogen) using 1150 V pulse voltage, 30 ms pulse width, and two pulses. U2OS<sup>CDK2</sup> and MCF10A cells (4 × 10<sup>4</sup>) were transfected using Lipofectamine 3000 Transfection Reagent (L3000001, Thermo Fisher) according to the manufacturer’s instructions. MISSION microRNA Mimic <italic>hsa-let-7a</italic> (HMI0003, Sigma), miRNA Mimic Negative Control (ABM-MCH00000, abm), and Anti-miR miRNA Inhibitor (AM17000, Thermo Fisher) were co-transfected by Lipofectamine RNAiMAX Transfection Reagent (13778100, Thermo Fisher) according to the manufacturer’s instructions. All analyses were carried out 24 hr post transfection.</p></sec><sec id="s4-5"><title>Live-cell fluorescence microscopy</title><p>Live-cell microscopy was performed using Olympus IX81 motorized inverted microscope, Orca CCD camera (Hamamatsu Photonics, Japan), motorized stage (Prior Scientific, Cambridge, UK), and 37°C incubation chamber (Solent Scientific, Segensworth, UK) fitted with appropriate filter sets and a 40× NA 1.42 oil objective. Images were collected in the 490 nm (Venus, sfGFP), 550 nm (mCherry), and 435 nm (CFP) channels using Micro-Manager software (<xref ref-type="bibr" rid="bib19">Edelstein et al., 2014</xref>). Image analysis was performed using a customized plug-in tool in ImageJ (<xref ref-type="bibr" rid="bib58">Schindelin et al., 2012</xref>), which calculates mean fluorescence intensity (MFI) by measuring average, background-subtracted gray values over regions of interest (ROIs) of defined diameter around manually selected points in the cell.</p></sec><sec id="s4-6"><title>Western blot</title><p>Western blot was performed as previously described (<xref ref-type="bibr" rid="bib1">Abdelbaki et al., 2020</xref>). PageRuler Pre-stained Protein Ladder (26616, Thermo Fisher) was used. Primary antibodies were mouse anti-AURKA (1:1000; Clone 4/IAK1, BD Transduction Laboratories), rabbit anti-GFP (1:5000; ab290, Abcam), rabbit anti-GAPDH (1:4000; 2118S, CST), rabbit anti-mCherry (1:1000; ab167453, Abcam), mouse anti-Flag M2 (1:1000; F1804, Sigma). Secondary antibodies were rabbit (P044801-2) or mouse (P044701-2) HRP-conjugated (Dako, Agilent), used at 1:10000 dilution, and detection was performed via Immobilon Western Chemiluminescent HRP Substrate (WBKLS0100, Millipore) on an Odyssey Fc Dual-Mode Imaging System (LI-COR Biosciences).</p></sec><sec id="s4-7"><title>RNA extraction and RT-qPCR</title><p>RNA extracts were collected using Total RNA miniprep kit (T2010S, NEB). DNA was in-column digested with DNase I. Aliquots were stored with 5 μM EDTA at –20°C for a week or flash-frozen in dry ice and transferred at –80°C. A micro-volume spectrophotometer (NanoDrop Lite, VWR) was used to assess A<sub>260</sub>/A<sub>280</sub> ratios of ~2.0 and A<sub>260</sub>/A<sub>230</sub> ratios of 2.0–2.2. RT-qPCR was performed using Luna Universal One-Step RT-qPCR Kit (E3005S, NEB). 20 µl reactions using 200 nM primers and &lt;100 ng RNA were run on ABI StepOnePlus Real Time PCR system following the manufacturer’s instructions. Primers were designed at Eurofins Genomics. ΔC<sub>t</sub> or ΔΔC<sub>t</sub> method was used for relative quantifications accounting for the primer pairs amplification efficiency. Three technical replicates were performed in each biological replicate. Results shown as mean and SEM of three biological replicates. Assessment of DNA contamination, sequences of primers, validation of amplification efficiency of primer pairs, and RT-qPCR reaction conditions are provided (Appendix 1-figures 1-11, Appendix 1-table 1, Appendix 1-table 2). Checklist of MIQE guidelines (<xref ref-type="bibr" rid="bib11">Bustin et al., 2009</xref>) can be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-8"><title>mRNA decay measurement</title><p>Cells were treated with 10 μg/ml actinomycin D (ActD) (10043673, Fisher Scientific) and RNA was isolated from cells at the indicated time points after inhibition of transcription. Target mRNA was quantified by RT-qPCR using the ΔΔC<sub>t</sub> method with indicated reference targets and corresponding RNA extracts at 0 hr of ActD treatment as reference sample. Mean and SEM of three biological replicates are shown at each time point.</p></sec><sec id="s4-9"><title>Nascent chain immunoprecipitation</title><p>Transfected cells were treated with 0.1 mg/ml CHX for 15 min, then washed, centrifuged, and resuspended in ice-cold lysis buffer (100 mM Tris-HCl pH 7.5 [BP1757-100, Fisher Scientific], 500 mM LiCl [L7026, Sigma], 10 mM EDTA [10458654, Invitrogen], 0.1 mg/ml CHX, 0.1% Triton X-100 [28817.295, VWR], 100 U/ml RNasIn [3335399001, Merck], and cOmplete EDTA-free protease inhibitor cocktail [11836170001, Roche]) and incubated 15 min on ice. Lysates were cleared by centrifugation and supernatant was incubated with anti-Flag M2 magnetic beads (M8823, Sigma) overnight at 4°C rotating. The bound fraction was washed twice (10 mM Tris-HCl pH 7.5, 600 mM LiCl, 1 mM EDTA, 100 U/ml RNasin, 0.1 mg/ml CHX). Followed elution with 10 mM Tris-HCl pH 7.5, 600 mM LiCl, 1 mM EDTA, 100 U/ml RNAsIn, 0.1 mg/ml puromycin (J67236.XF, Alfa Aesar), or with 3XFLAG peptide buffer (F4799, Sigma), for 30 min rotating at 4°C. RNA was purified (Monarch RNA Cleanup Kit, T2040L, NEB) from fractions and samples were stored as above. Aliquots of each fraction were mixed 1:1 with NuPAGE LDS Sample Buffer 4X (NP0007, Invitrogen) and 10 mM DTT (10197777001, Sigma), boiled 3 min at 95°C and stored at –20°C.</p></sec><sec id="s4-10"><title>3′RACE</title><p>cDNA synthesis was performed using the Transcriptor Reverse Transcriptase (3531317001, Roche) with an oligo-dT anchor primer (5′-<named-content content-type="sequence">GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTT</named-content>V-3′). In the first round of PCR, an AURKA-specific forward primer (5′-<named-content content-type="sequence">TCCATCTTCCAGGAGGACCACTCTCTG</named-content>-3′) was used with a reverse primer for the oligo-dT anchor sequence (Anchor_R: 5′-<named-content content-type="sequence">GACCACGCGTATCGATGTCGAC</named-content>-3′). In the second round of PCR (nested), a new AURKA-specific forward primer (5′-<named-content content-type="sequence">CGGGATCCATATCACGGGTTGAATTCACATTC</named-content>-3′) was used with Anchor_R. Nested PCR was performed using a 1:10 dilution of first PCR product as template. PCR product was visualized in agarose gels and imaged as above.</p></sec><sec id="s4-11"><title>Generation of ΔdPAS cell lines</title><p>Two guide RNAs (gRNA1: 5′-<named-content content-type="sequence">GGCCAACAATGAACAGATGG</named-content>-3′ and gRNA2: 5′-<named-content content-type="sequence">GAGCAGGGGCTGAGAGGAGC</named-content>-3′) were cloned into AIO-GFP (<xref ref-type="bibr" rid="bib14">Chiang et al., 2016</xref>), a gift from Steve Jackson (Addgene plasmid #74119). The donor DNA template for homology-directed repair (HDR) was cloned into a separate vector expressing mRuby (mRuby-HDR). AIO-GFP-gRNAs and mRuby-HDR were co-transfected into U2OS cells and 48 hr after transfection GFP<sup>+</sup>mRuby<sup>+</sup> cells were sorted at single-cell density into multiple 96-well plates for clonal expansion. Cell populations were individually screened for dPAS mutation by touch-down PCR. Mutants were confirmed by Sanger sequencing of the genomic locus.</p></sec><sec id="s4-12"><title>Cell counting kit-8 (CCK-8) assay</title><p>Cells were seeded into 96-well plates at a density of 4000 cells/well. CCK-8 (96992, Merck) was used according to the manufacturer’s instructions and measurements were performed at the indicated time points. The OD<sub>450</sub> value was determined using a CLARIOstar Plus microplate reader (BMG LABTECH). Mean and SEM of three biological replicates shown for each time point.</p></sec><sec id="s4-13"><title>Colony formation assay in soft agar</title><p>A 0.6% base agarose was prepared in 6-well plates, and cells were seeded at density of 15,000 cells per well prior mixing with agarose to a final agarose concentration of 0.3%. Fresh medium was added every 3 d. Colonies were imaged and counted after 10 d using phase contrast microscopy under 4× magnification.</p></sec><sec id="s4-14"><title>Migration assay</title><p>A suspension of 50,000 cells was added to each well of a Culture-Insert 2 Well (IB-80209, Thistle Scientific Ltd) and grown into a monolayer. After insert removal, cells were washed and serum-free medium was added. At indicated time points, images of three different fields were acquired for every condition using phase contrast microscopy under 10× magnification. The percentage of cell-free area was calculated using Wound_healing_size_tool plugin (<xref ref-type="bibr" rid="bib63">Suarez-Arnedo et al., 2020</xref>) in ImageJ and is shown as mean of three fields and SEM for three biological replicates.</p></sec><sec id="s4-15"><title>Statistical analyses</title><p>GraphPad Prism 9 (version 9.5.0; GraphPad Software Inc) and Microsoft Excel (version 16.72; Microsoft Corporation) were used to analyze data, generate graphs, and perform statistical analyses. Statistical parameters, including the sample size, the statistical test used, statistical significance (p-value), and the number of biological replicates, are reported in the figure legends or in the ‘Materials and methods.’.</p></sec><sec id="s4-16"><title>Materials availability</title><p>Materials from this study are available from the corresponding author upon reasonable request.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Software, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Software</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Software, Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-87253-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>MIQE guidelines checklist.</title></caption><media xlink:href="elife-87253-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The data underlying this article are available in the article and in its supporting files.</p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Karn</surname><given-names>T</given-names></name><name><surname>Rody</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>V</given-names></name><name><surname>Holtrich</surname><given-names>U</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name><name><surname>Kaufmann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><data-title>A Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse31519">GSE31519</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>KA</given-names></name><name><surname>Rosenberg</surname><given-names>CL</given-names></name><name><surname>Sebastiani</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>Histologically normal epithelium from breast cancer patients and cancer-free prophylactic mastectomy patients</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20437">GSE20437</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>C</given-names></name><name><surname>de la Morenas</surname><given-names>A</given-names></name><name><surname>Perry</surname><given-names>KV</given-names></name><name><surname>Burke</surname><given-names>B</given-names></name><name><surname>Antoine</surname><given-names>G</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Kavanah</surname><given-names>M</given-names></name><name><surname>Mendez</surname><given-names>J</given-names></name><name><surname>Stone</surname><given-names>M</given-names></name><name><surname>Gerry</surname><given-names>N</given-names></name><name><surname>Lenburg</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><data-title>Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9574">GSE9574</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><data-title>Human breast tumor expression</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3744">GSE3744</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset5"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Dalerba</surname><given-names>P</given-names></name><name><surname>Gurney</surname><given-names>A</given-names></name><name><surname>Hoey</surname><given-names>T</given-names></name><name><surname>Sherlock</surname><given-names>G</given-names></name><name><surname>Lewicki</surname><given-names>J</given-names></name><name><surname>Shedden</surname><given-names>K</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><data-title>The prognostic role of a gene signature from tumorigenic breast-cancer cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6883">GSE6883</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset6"><person-group person-group-type="author"><name><surname>Planche</surname><given-names>A</given-names></name><name><surname>Bacac</surname><given-names>M</given-names></name><name><surname>Provero</surname><given-names>P</given-names></name><name><surname>Fusco</surname><given-names>C</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name><name><surname>Stehle</surname><given-names>J</given-names></name><name><surname>Stamenkovic</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2011">2011</year><data-title>Stromal molecular signatures of breast and prostate cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26910">GSE26910</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset7"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>C</given-names></name><name><surname>Kemmner</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2011">2011</year><data-title>Expression profiling of human DCIS and invasive ductal breast carcinoma</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21422">GSE21422</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank past and present members of Lindon Lab for enriching discussions throughout the study. We are grateful to Chiara Marcozzi for advice on CRISPR/Cas9 and to Tim Weil, Adrien Rousseau, and Francesco Nicassio for insightful comments. Cartoon figures were created using <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">https://www.biorender.com/</ext-link>. This work was supported by Biotechnology and Biological Sciences Research Council (BBSRC) (grant no. BB/R004137/1) to CL. RC is supported by David James Studentship from the Department of Pharmacology.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelbaki</surname><given-names>A</given-names></name><name><surname>Akman</surname><given-names>HB</given-names></name><name><surname>Poteau</surname><given-names>M</given-names></name><name><surname>Grant</surname><given-names>R</given-names></name><name><surname>Gavet</surname><given-names>O</given-names></name><name><surname>Guarguaglini</surname><given-names>G</given-names></name><name><surname>Lindon</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>AURKA destruction is Decoupled from its activity at mitotic exit but is essential to suppress Interphase activity</article-title><source>Journal of Cell Science</source><volume>133</volume><elocation-id>jcs243071</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.243071</pub-id><pub-id pub-id-type="pmid">32393600</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akman</surname><given-names>BH</given-names></name><name><surname>Can</surname><given-names>T</given-names></name><name><surname>Erson-Bensan</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Estrogen-induced upregulation and 3′-UTR shortening of Cdc6</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>10679</fpage><lpage>10688</lpage><pub-id pub-id-type="doi">10.1093/nar/gks855</pub-id><pub-id pub-id-type="pmid">22977174</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akman</surname><given-names>HB</given-names></name><name><surname>Oyken</surname><given-names>M</given-names></name><name><surname>Tuncer</surname><given-names>T</given-names></name><name><surname>Can</surname><given-names>T</given-names></name><name><surname>Erson-Bensan</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>3’UTR shortening and EGF signaling: implications for breast cancer</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>6910</fpage><lpage>6920</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv391</pub-id><pub-id pub-id-type="pmid">26395459</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anda</surname><given-names>S</given-names></name><name><surname>Grallert</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cell-cycle-dependent regulation of translation: new interpretations of old observations in light of new approaches</article-title><source>BioEssays</source><volume>41</volume><elocation-id>e1900022</elocation-id><pub-id pub-id-type="doi">10.1002/bies.201900022</pub-id><pub-id pub-id-type="pmid">31210378</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asteriti</surname><given-names>IA</given-names></name><name><surname>Rensen</surname><given-names>WM</given-names></name><name><surname>Lindon</surname><given-names>C</given-names></name><name><surname>Lavia</surname><given-names>P</given-names></name><name><surname>Guarguaglini</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The Aurora-A/Tpx2 complex: A novel oncogenic holoenzyme</article-title><source>Biochimica et Biophysica Acta - Reviews on Cancer</source><volume>1806</volume><fpage>230</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2010.08.001</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avery-Kiejda</surname><given-names>KA</given-names></name><name><surname>Braye</surname><given-names>SG</given-names></name><name><surname>Mathe</surname><given-names>A</given-names></name><name><surname>Forbes</surname><given-names>JF</given-names></name><name><surname>Scott</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Decreased expression of key tumour Suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer</article-title><source>BMC Cancer</source><volume>14</volume><elocation-id>51</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-14-51</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aviner</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The science of puromycin: from studies of Ribosome function to applications in biotechnology</article-title><source>Computational and Structural Biotechnology Journal</source><volume>18</volume><fpage>1074</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2020.04.014</pub-id><pub-id pub-id-type="pmid">32435426</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolin</surname><given-names>G</given-names></name><name><surname>Tramier</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Insights into the non-mitotic functions of Aurora kinase A: more than just cell division</article-title><source>Cellular and Molecular Life Sciences</source><volume>77</volume><fpage>1031</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03310-2</pub-id><pub-id pub-id-type="pmid">31562563</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biasini</surname><given-names>A</given-names></name><name><surname>Abdulkarim</surname><given-names>B</given-names></name><name><surname>de Pretis</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>JY</given-names></name><name><surname>Arora</surname><given-names>R</given-names></name><name><surname>Wischnewski</surname><given-names>H</given-names></name><name><surname>Dreos</surname><given-names>R</given-names></name><name><surname>Pelizzola</surname><given-names>M</given-names></name><name><surname>Ciaudo</surname><given-names>C</given-names></name><name><surname>Marques</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Translation is required for miRNA‐Dependent decay of endogenous transcripts</article-title><source>The EMBO Journal</source><volume>40</volume><elocation-id>e104569</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2020104569</pub-id><pub-id pub-id-type="pmid">33300180</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bueno</surname><given-names>MJ</given-names></name><name><surname>Malumbres</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Micrornas and the cell cycle</article-title><source>Biochimica et Biophysica Acta - Molecular Basis of Disease</source><volume>1812</volume><fpage>592</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2011.02.002</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bustin</surname><given-names>SA</given-names></name><name><surname>Benes</surname><given-names>V</given-names></name><name><surname>Garson</surname><given-names>JA</given-names></name><name><surname>Hellemans</surname><given-names>J</given-names></name><name><surname>Huggett</surname><given-names>J</given-names></name><name><surname>Kubista</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>R</given-names></name><name><surname>Nolan</surname><given-names>T</given-names></name><name><surname>Pfaffl</surname><given-names>MW</given-names></name><name><surname>Shipley</surname><given-names>GL</given-names></name><name><surname>Vandesompele</surname><given-names>J</given-names></name><name><surname>Wittwer</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments</article-title><source>Clinical Chemistry</source><volume>55</volume><fpage>611</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2008.112797</pub-id><pub-id pub-id-type="pmid">19246619</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cacioppo</surname><given-names>R</given-names></name><name><surname>Lindon</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Regulating the regulator: a survey of mechanisms from transcription to translation controlling expression of mammalian cell cycle kinase Aurora A</article-title><source>Open Biology</source><volume>12</volume><elocation-id>220134</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.220134</pub-id><pub-id pub-id-type="pmid">36067794</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mirdb: an Online database for prediction of functional microRNA targets</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D127</fpage><lpage>D131</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz757</pub-id><pub-id pub-id-type="pmid">31504780</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>T-WW</given-names></name><name><surname>le Sage</surname><given-names>C</given-names></name><name><surname>Larrieu</surname><given-names>D</given-names></name><name><surname>Demir</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CRISPR-Cas9D10A Nickase-based Genotypic and Phenotypic screening to enhance genome editing</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>24356</elocation-id><pub-id pub-id-type="doi">10.1038/srep24356</pub-id><pub-id pub-id-type="pmid">27079678</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derti</surname><given-names>A</given-names></name><name><surname>Garrett-Engele</surname><given-names>P</given-names></name><name><surname>Macisaac</surname><given-names>KD</given-names></name><name><surname>Stevens</surname><given-names>RC</given-names></name><name><surname>Sriram</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Rohl</surname><given-names>CA</given-names></name><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Babak</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A quantitative Atlas of Polyadenylation in five mammals</article-title><source>Genome Research</source><volume>22</volume><fpage>1173</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1101/gr.132563.111</pub-id><pub-id pub-id-type="pmid">22454233</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobson</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Krushel</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dysregulating IRES-dependent translation contributes to overexpression of Oncogenic Aurora A kinase</article-title><source>Molecular Cancer Research</source><volume>11</volume><fpage>887</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-12-0707</pub-id><pub-id pub-id-type="pmid">23661421</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez</surname><given-names>D</given-names></name><name><surname>Tsai</surname><given-names>YH</given-names></name><name><surname>Weatheritt</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Blencowe</surname><given-names>BJ</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An extensive program of periodic alternative splicing linked to cell cycle progression</article-title><source>eLife</source><volume>5</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.10288</pub-id><pub-id pub-id-type="pmid">27015110</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy</article-title><source>Molecular Cancer</source><volume>20</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-020-01305-3</pub-id><pub-id pub-id-type="pmid">33451333</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edelstein</surname><given-names>AD</given-names></name><name><surname>Tsuchida</surname><given-names>MA</given-names></name><name><surname>Amodaj</surname><given-names>N</given-names></name><name><surname>Pinkard</surname><given-names>H</given-names></name><name><surname>Vale</surname><given-names>RD</given-names></name><name><surname>Stuurman</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Advanced methods of microscope control using Μmanager software</article-title><source>Journal of Biological Methods</source><volume>1</volume><elocation-id>e10</elocation-id><pub-id pub-id-type="doi">10.14440/jbm.2014.36</pub-id><pub-id pub-id-type="pmid">25606571</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadaka</surname><given-names>AO</given-names></name><name><surname>Sibuyi</surname><given-names>NRS</given-names></name><name><surname>Madiehe</surname><given-names>AM</given-names></name><name><surname>Meyer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Microrna-based regulation of Aurora A kinase in breast cancer</article-title><source>Oncotarget</source><volume>11</volume><fpage>4306</fpage><lpage>4324</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.27811</pub-id><pub-id pub-id-type="pmid">33245732</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghafouri-Fard</surname><given-names>S</given-names></name><name><surname>Shoorei</surname><given-names>H</given-names></name><name><surname>Anamag</surname><given-names>FT</given-names></name><name><surname>Taheri</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of non-coding Rnas in controlling cell cycle related proteins in cancer cells</article-title><source>Frontiers in Oncology</source><volume>10</volume><elocation-id>608975</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.608975</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>K</given-names></name><name><surname>de las Morenas</surname><given-names>A</given-names></name><name><surname>Tripathi</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>C</given-names></name><name><surname>Kavanah</surname><given-names>M</given-names></name><name><surname>Mendez</surname><given-names>J</given-names></name><name><surname>Stone</surname><given-names>M</given-names></name><name><surname>Slama</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Antoine</surname><given-names>G</given-names></name><name><surname>Willers</surname><given-names>H</given-names></name><name><surname>Sebastiani</surname><given-names>P</given-names></name><name><surname>Rosenberg</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile</article-title><source>British Journal of Cancer</source><volume>102</volume><fpage>1284</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605576</pub-id><pub-id pub-id-type="pmid">20197764</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>R</given-names></name><name><surname>Abdelbaki</surname><given-names>A</given-names></name><name><surname>Bertoldi</surname><given-names>A</given-names></name><name><surname>Gavilan</surname><given-names>MP</given-names></name><name><surname>Mansfeld</surname><given-names>J</given-names></name><name><surname>Glover</surname><given-names>DM</given-names></name><name><surname>Lindon</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Constitutive regulation of mitochondrial morphology by Aurora A kinase depends on a predicted cryptic targeting sequence at the N-terminus</article-title><source>Open Biology</source><volume>8</volume><elocation-id>170272</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.170272</pub-id><pub-id pub-id-type="pmid">29899121</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grolmusz</surname><given-names>VK</given-names></name><name><surname>Tóth</surname><given-names>EA</given-names></name><name><surname>Baghy</surname><given-names>K</given-names></name><name><surname>Likó</surname><given-names>I</given-names></name><name><surname>Darvasi</surname><given-names>O</given-names></name><name><surname>Kovalszky</surname><given-names>I</given-names></name><name><surname>Matkó</surname><given-names>J</given-names></name><name><surname>Rácz</surname><given-names>K</given-names></name><name><surname>Patócs</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fluorescence activated cell sorting followed by small RNA sequencing reveals stable microRNA expression during cell cycle progression</article-title><source>BMC Genomics</source><volume>17</volume><elocation-id>412</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-016-2747-6</pub-id><pub-id pub-id-type="pmid">27234232</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruber</surname><given-names>AJ</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Gruber</surname><given-names>AR</given-names></name><name><surname>Martin</surname><given-names>G</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Belmadani</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>W</given-names></name><name><surname>Zavolan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A comprehensive analysis of 3’ end sequencing data SETS reveals novel Polyadenylation signals and the repressive role of heterogeneous Ribonucleoprotein C on cleavage and Polyadenylation</article-title><source>Genome Research</source><volume>26</volume><fpage>1145</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1101/gr.202432.115</pub-id><pub-id pub-id-type="pmid">27382025</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruber</surname><given-names>AJ</given-names></name><name><surname>Zavolan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Alternative cleavage and Polyadenylation in health and disease</article-title><source>Nature Reviews. Genetics</source><volume>20</volume><fpage>599</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1038/s41576-019-0145-z</pub-id><pub-id pub-id-type="pmid">31267064</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>K</given-names></name><name><surname>Jaimovich</surname><given-names>A</given-names></name><name><surname>Dey</surname><given-names>G</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name><name><surname>Meyuhas</surname><given-names>O</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Parallel measurement of dynamic changes in translation rates in single cells</article-title><source>Nature Methods</source><volume>11</volume><fpage>86</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2729</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinnebusch</surname><given-names>AG</given-names></name><name><surname>Ivanov</surname><given-names>IP</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Translational control by 5′-Untranslated regions of Eukaryotic mRNAs</article-title><source>Science</source><volume>352</volume><fpage>1413</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1126/science.aad9868</pub-id><pub-id pub-id-type="pmid">27313038</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalalirad</surname><given-names>M</given-names></name><name><surname>Haddad</surname><given-names>TC</given-names></name><name><surname>Salisbury</surname><given-names>JL</given-names></name><name><surname>Radisky</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name><name><surname>Tuma</surname><given-names>A</given-names></name><name><surname>Leof</surname><given-names>E</given-names></name><name><surname>Carter</surname><given-names>JM</given-names></name><name><surname>Degnim</surname><given-names>AC</given-names></name><name><surname>Boughey</surname><given-names>JC</given-names></name><name><surname>Sarkaria</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>MC</given-names></name><name><surname>Zammataro</surname><given-names>L</given-names></name><name><surname>Malatino</surname><given-names>L</given-names></name><name><surname>Galanis</surname><given-names>E</given-names></name><name><surname>Ingle</surname><given-names>JN</given-names></name><name><surname>Goetz</surname><given-names>MP</given-names></name><name><surname>D’Assoro</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Aurora-A kinase Oncogenic signaling mediates TGF-Β-induced triple-negative breast cancer plasticity and Chemoresistance</article-title><source>Oncogene</source><volume>40</volume><fpage>2509</fpage><lpage>2523</lpage><pub-id pub-id-type="doi">10.1038/s41388-021-01711-x</pub-id><pub-id pub-id-type="pmid">33674749</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>CD</given-names></name><name><surname>Esquela-Kerscher</surname><given-names>A</given-names></name><name><surname>Stefani</surname><given-names>G</given-names></name><name><surname>Byrom</surname><given-names>M</given-names></name><name><surname>Kelnar</surname><given-names>K</given-names></name><name><surname>Ovcharenko</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shelton</surname><given-names>J</given-names></name><name><surname>Shingara</surname><given-names>J</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Slack</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The Let-7 microRNA represses cell proliferation pathways in human cells</article-title><source>Cancer Research</source><volume>67</volume><fpage>7713</fpage><lpage>7722</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1083</pub-id><pub-id pub-id-type="pmid">17699775</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>S</given-names></name><name><surname>Izaurralde</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Towards a molecular understanding of microRNA-mediated Gene silencing</article-title><source>Nature Reviews. Genetics</source><volume>16</volume><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1038/nrg3965</pub-id><pub-id pub-id-type="pmid">26077373</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovalski</surname><given-names>JR</given-names></name><name><surname>Kuzuoglu-Ozturk</surname><given-names>D</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Protein synthesis control in cancer: selectivity and therapeutic targeting</article-title><source>The EMBO Journal</source><volume>41</volume><elocation-id>e109823</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2021109823</pub-id><pub-id pub-id-type="pmid">35315941</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kretschmer</surname><given-names>C</given-names></name><name><surname>Sterner-Kock</surname><given-names>A</given-names></name><name><surname>Siedentopf</surname><given-names>F</given-names></name><name><surname>Schoenegg</surname><given-names>W</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name><name><surname>Kemmner</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Identification of early molecular markers for breast cancer</article-title><source>Molecular Cancer</source><volume>10</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/1476-4598-10-15</pub-id><pub-id pub-id-type="pmid">21314937</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C-H</given-names></name><name><surname>Huang</surname><given-names>Y-C</given-names></name><name><surname>Lee</surname><given-names>J-C</given-names></name><name><surname>Tseng</surname><given-names>JT-C</given-names></name><name><surname>Chang</surname><given-names>K-C</given-names></name><name><surname>Chen</surname><given-names>Y-J</given-names></name><name><surname>Ding</surname><given-names>N-J</given-names></name><name><surname>Huang</surname><given-names>P-H</given-names></name><name><surname>Chang</surname><given-names>W-C</given-names></name><name><surname>Lin</surname><given-names>B-W</given-names></name><name><surname>Chen</surname><given-names>R-Y</given-names></name><name><surname>Wang</surname><given-names>Y-C</given-names></name><name><surname>Lai</surname><given-names>Y-C</given-names></name><name><surname>Hung</surname><given-names>L-Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Translational upregulation of Aurora-A by hnRNP Q1 contributes to cell proliferation and tumorigenesis in colorectal cancer</article-title><source>Cell Death &amp; Disease</source><volume>8</volume><elocation-id>e2555</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2016.479</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Tisdale</surname><given-names>S</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Leslie</surname><given-names>CS</given-names></name><name><surname>Mayr</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia</article-title><source>Nature</source><volume>561</volume><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0465-8</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lembo</surname><given-names>A</given-names></name><name><surname>Di Cunto</surname><given-names>F</given-names></name><name><surname>Provero</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Shortening of 3′Utrs correlates with poor prognosis in breast and lung cancer</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e31129</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0031129</pub-id><pub-id pub-id-type="pmid">22347440</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C-S</given-names></name><name><surname>Lee</surname><given-names>H-T</given-names></name><name><surname>Lee</surname><given-names>M-H</given-names></name><name><surname>Pan</surname><given-names>S-C</given-names></name><name><surname>Ke</surname><given-names>C-Y</given-names></name><name><surname>Chiu</surname><given-names>AW-H</given-names></name><name><surname>Wei</surname><given-names>Y-H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Role of mitochondrial DNA copy number alteration in human renal cell carcinoma</article-title><source>International Journal of Molecular Sciences</source><volume>17</volume><elocation-id>814</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17060814</pub-id><pub-id pub-id-type="pmid">27231905</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindon</surname><given-names>C</given-names></name><name><surname>Grant</surname><given-names>R</given-names></name><name><surname>Min</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ubiquitin-mediated degradation of Aurora Kinases</article-title><source>Frontiers in Oncology</source><volume>5</volume><elocation-id>307</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2015.00307</pub-id><pub-id pub-id-type="pmid">26835416</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>GY</given-names></name><name><surname>Dalerba</surname><given-names>P</given-names></name><name><surname>Gurney</surname><given-names>A</given-names></name><name><surname>Hoey</surname><given-names>T</given-names></name><name><surname>Sherlock</surname><given-names>G</given-names></name><name><surname>Lewicki</surname><given-names>J</given-names></name><name><surname>Shedden</surname><given-names>K</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The Prognostic role of a Gene signature from Tumorigenic breast-cancer cells</article-title><source>The New England Journal of Medicine</source><volume>356</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa063994</pub-id><pub-id pub-id-type="pmid">17229949</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>ZL</given-names></name><name><surname>Zhang</surname><given-names>BJ</given-names></name><name><surname>Wang</surname><given-names>DT</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>JL</given-names></name><name><surname>Zhao</surname><given-names>BT</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>YL</given-names></name><name><surname>Jin</surname><given-names>YX</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer</article-title><source>Oncotarget</source><volume>6</volume><fpage>20111</fpage><lpage>20120</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3933</pub-id><pub-id pub-id-type="pmid">26036635</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masamha</surname><given-names>CP</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Albrecht</surname><given-names>TR</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Shyu</surname><given-names>AB</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wagner</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cfim25 links alternative Polyadenylation to glioblastoma tumour suppression</article-title><source>Nature</source><volume>510</volume><fpage>412</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/nature13261</pub-id><pub-id pub-id-type="pmid">24814343</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>C</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Widespread shortening of 3′Utrs by alternative cleavage and Polyadenylation activates Oncogenes in cancer cells</article-title><source>Cell</source><volume>138</volume><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.06.016</pub-id><pub-id pub-id-type="pmid">19703394</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>WO</given-names></name><name><surname>Lembo</surname><given-names>A</given-names></name><name><surname>Volorio</surname><given-names>A</given-names></name><name><surname>Brachtel</surname><given-names>E</given-names></name><name><surname>Tian</surname><given-names>B</given-names></name><name><surname>Sgroi</surname><given-names>D</given-names></name><name><surname>Provero</surname><given-names>P</given-names></name><name><surname>Dyson</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Alternative Polyadenylation in triple-negative breast tumors allows NRAS and C-JUN to bypass PUMILIO Posttranscriptional regulation</article-title><source>Cancer Research</source><volume>76</volume><fpage>7231</fpage><lpage>7241</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-0844</pub-id><pub-id pub-id-type="pmid">27758885</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitschka</surname><given-names>S</given-names></name><name><surname>Mayr</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Context-specific regulation and function of mRNA alternative Polyadenylation</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>23</volume><fpage>779</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1038/s41580-022-00507-5</pub-id><pub-id pub-id-type="pmid">35798852</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modelska</surname><given-names>A</given-names></name><name><surname>Turro</surname><given-names>E</given-names></name><name><surname>Russell</surname><given-names>R</given-names></name><name><surname>Beaton</surname><given-names>J</given-names></name><name><surname>Sbarrato</surname><given-names>T</given-names></name><name><surname>Spriggs</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Gräf</surname><given-names>S</given-names></name><name><surname>Provenzano</surname><given-names>E</given-names></name><name><surname>Blows</surname><given-names>F</given-names></name><name><surname>Pharoah</surname><given-names>P</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Le Quesne</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The malignant phenotype in breast cancer is driven by Eif4A1-mediated changes in the Translational landscape</article-title><source>Cell Death &amp; Disease</source><volume>6</volume><elocation-id>e1603</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2014.542</pub-id><pub-id pub-id-type="pmid">25611378</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Ibata</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>ES</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><name><surname>Mikoshiba</surname><given-names>K</given-names></name><name><surname>Miyawaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications</article-title><source>Nature Biotechnology</source><volume>20</volume><fpage>87</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/nbt0102-87</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narula</surname><given-names>A</given-names></name><name><surname>Ellis</surname><given-names>J</given-names></name><name><surname>Taliaferro</surname><given-names>JM</given-names></name><name><surname>Rissland</surname><given-names>OS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Coding regions affect mRNA stability in human cells</article-title><source>RNA</source><volume>25</volume><fpage>1751</fpage><lpage>1764</lpage><pub-id pub-id-type="doi">10.1261/rna.073239.119</pub-id><pub-id pub-id-type="pmid">31527111</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naso</surname><given-names>FD</given-names></name><name><surname>Boi</surname><given-names>D</given-names></name><name><surname>Ascanelli</surname><given-names>C</given-names></name><name><surname>Pamfil</surname><given-names>G</given-names></name><name><surname>Lindon</surname><given-names>C</given-names></name><name><surname>Paiardini</surname><given-names>A</given-names></name><name><surname>Guarguaglini</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Nuclear Localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer</article-title><source>Oncogene</source><volume>40</volume><fpage>3917</fpage><lpage>3928</lpage><pub-id pub-id-type="doi">10.1038/s41388-021-01766-w</pub-id><pub-id pub-id-type="pmid">33981003</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nottrott</surname><given-names>S</given-names></name><name><surname>Simard</surname><given-names>MJ</given-names></name><name><surname>Richter</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Human Let-7A miRNA blocks protein production on actively translating Polyribosomes</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>13</volume><fpage>1108</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1038/nsmb1173</pub-id><pub-id pub-id-type="pmid">17128272</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Ji</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Rodriguez</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Masamha</surname><given-names>CP</given-names></name><name><surname>Baillat</surname><given-names>D</given-names></name><name><surname>Fontes-Garfias</surname><given-names>CR</given-names></name><name><surname>Shyu</surname><given-names>A-B</given-names></name><name><surname>Neilson</surname><given-names>JR</given-names></name><name><surname>Wagner</surname><given-names>EJ</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>3′ UTR shortening represses tumor-Suppressor genes in Trans by disrupting ceRNA Crosstalk</article-title><source>Nature Genetics</source><volume>50</volume><fpage>783</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0118-8</pub-id><pub-id pub-id-type="pmid">29785014</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pédelacq</surname><given-names>JD</given-names></name><name><surname>Cabantous</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Waldo</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Engineering and characterization of a Superfolder green fluorescent protein</article-title><source>Nature Biotechnology</source><volume>24</volume><fpage>79</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/nbt1172</pub-id><pub-id pub-id-type="pmid">16369541</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieraccioli</surname><given-names>M</given-names></name><name><surname>Caggiano</surname><given-names>C</given-names></name><name><surname>Mignini</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>C</given-names></name><name><surname>Babini</surname><given-names>G</given-names></name><name><surname>Lattanzio</surname><given-names>R</given-names></name><name><surname>Di Stasi</surname><given-names>S</given-names></name><name><surname>Tian</surname><given-names>B</given-names></name><name><surname>Sette</surname><given-names>C</given-names></name><name><surname>Bielli</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The transcriptional Terminator Xrn2 and the RNA-binding protein Sam68 link alternative Polyadenylation to cell cycle progression in prostate cancer</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>29</volume><fpage>1101</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1038/s41594-022-00853-0</pub-id><pub-id pub-id-type="pmid">36344846</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planche</surname><given-names>A</given-names></name><name><surname>Bacac</surname><given-names>M</given-names></name><name><surname>Provero</surname><given-names>P</given-names></name><name><surname>Fusco</surname><given-names>C</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name><name><surname>Stehle</surname><given-names>JC</given-names></name><name><surname>Stamenkovic</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Identification of Prognostic molecular features in the reactive Stroma of human breast and prostate cancer</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e18640</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018640</pub-id><pub-id pub-id-type="pmid">21611158</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>ZC</given-names></name><name><surname>De Nicolo</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Liao</surname><given-names>X</given-names></name><name><surname>Iglehart</surname><given-names>JD</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>X Chromosomal abnormalities in basal-like human breast cancer</article-title><source>Cancer Cell</source><volume>9</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.01.013</pub-id><pub-id pub-id-type="pmid">16473279</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rody</surname><given-names>A</given-names></name><name><surname>Karn</surname><given-names>T</given-names></name><name><surname>Liedtke</surname><given-names>C</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name><name><surname>Ruckhaeberle</surname><given-names>E</given-names></name><name><surname>Hanker</surname><given-names>L</given-names></name><name><surname>Gaetje</surname><given-names>R</given-names></name><name><surname>Solbach</surname><given-names>C</given-names></name><name><surname>Ahr</surname><given-names>A</given-names></name><name><surname>Metzler</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>V</given-names></name><name><surname>Holtrich</surname><given-names>U</given-names></name><name><surname>Kaufmann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A clinically relevant Gene signature in triple negative and basal-like breast cancer</article-title><source>Breast Cancer Research</source><volume>13</volume><elocation-id>R97</elocation-id><pub-id pub-id-type="doi">10.1186/bcr3035</pub-id><pub-id pub-id-type="pmid">21978456</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeed</surname><given-names>AI</given-names></name><name><surname>Sharov</surname><given-names>V</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Bhagabati</surname><given-names>N</given-names></name><name><surname>Braisted</surname><given-names>J</given-names></name><name><surname>Klapa</surname><given-names>M</given-names></name><name><surname>Currier</surname><given-names>T</given-names></name><name><surname>Thiagarajan</surname><given-names>M</given-names></name><name><surname>Sturn</surname><given-names>A</given-names></name><name><surname>Snuffin</surname><given-names>M</given-names></name><name><surname>Rezantsev</surname><given-names>A</given-names></name><name><surname>Popov</surname><given-names>D</given-names></name><name><surname>Ryltsov</surname><given-names>A</given-names></name><name><surname>Kostukovich</surname><given-names>E</given-names></name><name><surname>Borisovsky</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Vinsavich</surname><given-names>A</given-names></name><name><surname>Trush</surname><given-names>V</given-names></name><name><surname>Quackenbush</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Tm4: A free, open-source system for Microarray data management and analysis</article-title><source>BioTechniques</source><volume>34</volume><fpage>374</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.2144/03342mt01</pub-id><pub-id pub-id-type="pmid">12613259</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandberg</surname><given-names>R</given-names></name><name><surname>Neilson</surname><given-names>JR</given-names></name><name><surname>Sarma</surname><given-names>A</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Proliferating cells Express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites</article-title><source>Science</source><volume>320</volume><fpage>1643</fpage><lpage>1647</lpage><pub-id pub-id-type="doi">10.1126/science.1155390</pub-id><pub-id pub-id-type="pmid">18566288</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>J-Y</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaner</surname><given-names>NC</given-names></name><name><surname>Campbell</surname><given-names>RE</given-names></name><name><surname>Steinbach</surname><given-names>PA</given-names></name><name><surname>Giepmans</surname><given-names>BNG</given-names></name><name><surname>Palmer</surname><given-names>AE</given-names></name><name><surname>Tsien</surname><given-names>RY</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma SP: Red fluorescent protein</article-title><source>Nature Biotechnology</source><volume>22</volume><fpage>1567</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1038/nbt1037</pub-id><pub-id pub-id-type="pmid">15558047</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ran</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Hao</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Let-7A-5P inhibits triple-negative breast tumor growth and metastasis through Glut12-mediated Warburg effect</article-title><source>Cancer Letters</source><volume>495</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.09.012</pub-id><pub-id pub-id-type="pmid">32946964</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Alley</surname><given-names>TL</given-names></name><name><surname>Wright</surname><given-names>SM</given-names></name><name><surname>Kamdar</surname><given-names>S</given-names></name><name><surname>Schott</surname><given-names>W</given-names></name><name><surname>Wilpan</surname><given-names>RY</given-names></name><name><surname>Mills</surname><given-names>KD</given-names></name><name><surname>Graber</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Global changes in processing of mRNA 3′ untranslated regions characterize clinically distinct cancer subtypes</article-title><source>Cancer Research</source><volume>69</volume><fpage>9422</fpage><lpage>9430</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2236</pub-id><pub-id pub-id-type="pmid">19934316</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>SL</given-names></name><name><surname>Cappell</surname><given-names>SD</given-names></name><name><surname>Tsai</surname><given-names>FC</given-names></name><name><surname>Overton</surname><given-names>KW</given-names></name><name><surname>Wang</surname><given-names>CL</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The proliferation-Quiescence decision is controlled by a Bifurcation in Cdk2 activity at mitotic exit</article-title><source>Cell</source><volume>155</volume><fpage>369</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.08.062</pub-id><pub-id pub-id-type="pmid">24075009</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suarez-Arnedo</surname><given-names>A</given-names></name><name><surname>Torres Figueroa</surname><given-names>F</given-names></name><name><surname>Clavijo</surname><given-names>C</given-names></name><name><surname>Arbeláez</surname><given-names>P</given-names></name><name><surname>Cruz</surname><given-names>JC</given-names></name><name><surname>Muñoz-Camargo</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An image J Plugin for the high throughput image analysis of in vitro scratch wound healing assays</article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0232565</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0232565</pub-id><pub-id pub-id-type="pmid">32722676</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanenbaum</surname><given-names>ME</given-names></name><name><surname>Stern-Ginossar</surname><given-names>N</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name><name><surname>Vale</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of mRNA translation during Mitosis</article-title><source>eLife</source><volume>4</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.07957</pub-id><pub-id pub-id-type="pmid">26305499</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tat</surname><given-names>TT</given-names></name><name><surname>Maroney</surname><given-names>PA</given-names></name><name><surname>Chamnongpol</surname><given-names>S</given-names></name><name><surname>Coller</surname><given-names>J</given-names></name><name><surname>Nilsen</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cotranslational microRNA mediated messenger RNA Destabilization</article-title><source>eLife</source><volume>5</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.12880</pub-id><pub-id pub-id-type="pmid">27058298</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thammaiah</surname><given-names>CK</given-names></name><name><surname>Jayaram</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Role of Let-7 family microRNA in breast cancer</article-title><source>Non-Coding RNA Research</source><volume>1</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.ncrna.2016.10.003</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>C</given-names></name><name><surname>de la Morenas</surname><given-names>A</given-names></name><name><surname>Perry</surname><given-names>VK</given-names></name><name><surname>Burke</surname><given-names>B</given-names></name><name><surname>Antoine</surname><given-names>GA</given-names></name><name><surname>Hirsch</surname><given-names>EF</given-names></name><name><surname>Kavanah</surname><given-names>M</given-names></name><name><surname>Mendez</surname><given-names>J</given-names></name><name><surname>Stone</surname><given-names>M</given-names></name><name><surname>Gerry</surname><given-names>NP</given-names></name><name><surname>Lenburg</surname><given-names>ME</given-names></name><name><surname>Rosenberg</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients</article-title><source>International Journal of Cancer</source><volume>122</volume><fpage>1557</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1002/ijc.23267</pub-id><pub-id pub-id-type="pmid">18058819</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turashvili</surname><given-names>G</given-names></name><name><surname>Lightbody</surname><given-names>ED</given-names></name><name><surname>Tyryshkin</surname><given-names>K</given-names></name><name><surname>SenGupta</surname><given-names>SK</given-names></name><name><surname>Elliott</surname><given-names>BE</given-names></name><name><surname>Madarnas</surname><given-names>Y</given-names></name><name><surname>Ghaffari</surname><given-names>A</given-names></name><name><surname>Day</surname><given-names>A</given-names></name><name><surname>Nicol</surname><given-names>CJB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Novel Prognostic and predictive microRNA targets for triple-negative breast cancer</article-title><source>FASEB Journal</source><volume>32</volume><elocation-id>fj201800120R</elocation-id><pub-id pub-id-type="doi">10.1096/fj.201800120R</pub-id><pub-id pub-id-type="pmid">29812973</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tvingsholm</surname><given-names>SA</given-names></name><name><surname>Hansen</surname><given-names>MB</given-names></name><name><surname>Clemmensen</surname><given-names>KKB</given-names></name><name><surname>Brix</surname><given-names>DM</given-names></name><name><surname>Rafn</surname><given-names>B</given-names></name><name><surname>Frankel</surname><given-names>LB</given-names></name><name><surname>Louhimo</surname><given-names>R</given-names></name><name><surname>Moreira</surname><given-names>J</given-names></name><name><surname>Hautaniemi</surname><given-names>S</given-names></name><name><surname>Gromova</surname><given-names>I</given-names></name><name><surname>Jäättelä</surname><given-names>M</given-names></name><name><surname>Kallunki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Let-7 microRNA controls invasion-promoting lysosomal changes via the Oncogenic transcription factor myeloid zinc Finger-1</article-title><source>Oncogenesis</source><volume>7</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.1038/s41389-017-0014-6</pub-id><pub-id pub-id-type="pmid">29396433</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Nambiar</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Tian</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Polya-DB 3 catalogs cleavage and Polyadenylation sites identified by deep sequencing in multiple Genomes</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D315</fpage><lpage>D319</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1000</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lang</surname><given-names>GT</given-names></name><name><surname>Xue</surname><given-names>MZ</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>XG</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dissecting the heterogeneity of the alternative Polyadenylation profiles in triple-negative breast cancers</article-title><source>Theranostics</source><volume>10</volume><fpage>10531</fpage><lpage>10547</lpage><pub-id pub-id-type="doi">10.7150/thno.40944</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willems</surname><given-names>E</given-names></name><name><surname>Dedobbeleer</surname><given-names>M</given-names></name><name><surname>Digregorio</surname><given-names>M</given-names></name><name><surname>Lombard</surname><given-names>A</given-names></name><name><surname>Lumapat</surname><given-names>PN</given-names></name><name><surname>Rogister</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The functional diversity of Aurora Kinases: A comprehensive review</article-title><source>Cell Division</source><volume>13</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/s13008-018-0040-6</pub-id><pub-id pub-id-type="pmid">30250494</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>TD</given-names></name><name><surname>Cacioppo</surname><given-names>R</given-names></name><name><surname>Agrotis</surname><given-names>A</given-names></name><name><surname>Black</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Rousseau</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Actin remodelling controls Proteasome homeostasis upon stress</article-title><source>Nature Cell Biology</source><volume>24</volume><fpage>1077</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1038/s41556-022-00938-4</pub-id><pub-id pub-id-type="pmid">35739319</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Donehower</surname><given-names>LA</given-names></name><name><surname>Cooper</surname><given-names>TA</given-names></name><name><surname>Neilson</surname><given-names>JR</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Wagner</surname><given-names>EJ</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dynamic analyses of alternative Polyadenylation from RNA-Seq reveal a 3’-UTR landscape across seven tumour types</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>5274</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms6274</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Lou</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Mills</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>N-Y</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Muge Ozguc</surname><given-names>F</given-names></name><name><surname>Diao</surname><given-names>L</given-names></name><name><surname>Karmouty-Quintana</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Kellems</surname><given-names>RE</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Blackburn</surname><given-names>MR</given-names></name><name><surname>Yoo</surname><given-names>S-H</given-names></name><name><surname>Shyu</surname><given-names>A-B</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Han</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Comprehensive characterization of alternative Polyadenylation in human cancer</article-title><source>Journal of the National Cancer Institute</source><volume>110</volume><fpage>379</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1093/jnci/djx223</pub-id><pub-id pub-id-type="pmid">29106591</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Yue</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e56919</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0056919</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>YL</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Mu</surname><given-names>SM</given-names></name><name><surname>Dong</surname><given-names>YD</given-names></name><name><surname>Li</surname><given-names>DY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mir-26A-5P inhibits cell proliferation and enhances doxorubicin sensitivity in HCC cells via targeting AURKA</article-title><source>Technology in Cancer Research &amp; Treatment</source><volume>18</volume><elocation-id>1533033819851833</elocation-id><pub-id pub-id-type="doi">10.1177/1533033819851833</pub-id><pub-id pub-id-type="pmid">31570091</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Recce</surname><given-names>M</given-names></name><name><surname>Tian</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Polya_Db: A database for mammalian mRNA Polyadenylation</article-title><source>Nucleic Acids Research</source><volume>33</volume><fpage>D116</fpage><lpage>D120</lpage><pub-id pub-id-type="doi">10.1093/nar/gki055</pub-id><pub-id pub-id-type="pmid">15608159</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Bao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Huo</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Microrna-490-3p suppresses hepatocellular carcinoma cell proliferation and migration by targeting the Aurora kinase A Gene (AURKA)</article-title><source>Archives of Medical Science</source><volume>16</volume><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.5114/aoms.2019.91351</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Kuang</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Kuo</surname><given-names>WL</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name><name><surname>Sahin</surname><given-names>A</given-names></name><name><surname>Brinkley</surname><given-names>BR</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Tumour amplified kinase Stk15/BTAK induces Centrosome amplification, Aneuploidy and transformation</article-title><source>Nature Genetics</source><volume>20</volume><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1038/2496</pub-id><pub-id pub-id-type="pmid">9771714</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Sequences of primers and targets of primer pairs used in RT-qPCR.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Primer pair</th><th align="left" valign="bottom">Sequence</th><th align="left" valign="bottom">Target</th></tr></thead><tbody><tr><td align="left" valign="bottom">mCherry_F mCherry_R</td><td align="left" valign="bottom"><named-content content-type="sequence">CCGACATCCCCGACTACTTGAAGC</named-content> <named-content content-type="sequence">CACCTTGTAGATGAACTCGCCGTCC</named-content></td><td align="left" valign="bottom">mCherry ORF.</td></tr><tr><td align="left" valign="bottom">3′UTR_F 3′UTR_R</td><td align="left" valign="bottom"><named-content content-type="sequence">GCCCGACAACCACTACCTGAGCTAC</named-content> <named-content content-type="sequence">GCTCAAGGATTTCTCCCCCTGCAC</named-content></td><td align="left" valign="bottom">Reporter Venus mRNAs containing AURKA 3′UTR.</td></tr><tr><td align="left" valign="bottom">Venus_F Venus_R</td><td align="left" valign="bottom"><named-content content-type="sequence">CTGACCCTGAAGCTGATCT</named-content> <named-content content-type="sequence">GCATGGCGGACTTGAAGAAG</named-content></td><td align="left" valign="bottom">Venus ORF.</td></tr><tr><td align="left" valign="bottom">sfGFP_F sfGFP_R</td><td align="left" valign="bottom"><named-content content-type="sequence">GGCCCTGTCCTTTTACCAGACAACC</named-content> <named-content content-type="sequence">CATCCATGCCATGTGTAATCCCAGC</named-content></td><td align="left" valign="bottom">DHFR-sfGFP ORF.</td></tr><tr><td align="left" valign="bottom">18S_F 18S_R</td><td align="left" valign="bottom"><named-content content-type="sequence">CTCAACACGGGAAACCTCAC</named-content> <named-content content-type="sequence">CGCTCCACCAACTAAGAACG</named-content></td><td align="left" valign="bottom">18S ribosomal RNA<xref ref-type="table-fn" rid="app1table1fn1">*</xref> (NR_146146.1).</td></tr><tr><td align="left" valign="bottom">AURKA_Long_F AURKA_Long_R</td><td align="left" valign="bottom"><named-content content-type="sequence">GGCGAAGCCTGGTAAAGCTG</named-content> <named-content content-type="sequence">GCCTCTTCTGTATCCCAAGCAAATCC</named-content></td><td align="left" valign="bottom">All AURKA 5’UTR splice variants<xref ref-type="table-fn" rid="app1table1fn2"><sup>†</sup></xref> and only long 3′UTR APA isoform. Primer pair anneals to AURKA exon XI.</td></tr><tr><td align="left" valign="bottom">AURKA_Total_F AURKA_Total_R</td><td align="left" valign="bottom"><named-content content-type="sequence">TGTAACAGAGGGAGCCAGGGACC</named-content> <named-content content-type="sequence">TGATGAATTTGCTGTGATCCAGGGGTG</named-content></td><td align="left" valign="bottom">All AURKA 5′UTR splice variants<xref ref-type="table-fn" rid="app1table1fn2"><sup>†</sup></xref> and both 3′UTR APA isoforms.<break/>Primer pair anneals to AURKA exon XI.</td></tr><tr><td align="left" valign="bottom">AURKA_SLR_F AURKA_SLR_Short_R</td><td align="left" valign="bottom"><named-content content-type="sequence">TGCTAGGCATGGTGTCTTCA</named-content> <named-content content-type="sequence">AACAGCTTTACCAGGCTTCG</named-content></td><td align="left" valign="bottom">All AURKA 5′UTR splice variants<sup>†</sup> and both 3′UTR APA isoforms. Primer pair anneals to AURKA exon XI.</td></tr><tr><td align="left" valign="bottom">AURKA_SLR_F AURKA_SLR_Long_R</td><td align="left" valign="bottom"><named-content content-type="sequence">TGCTAGGCATGGTGTCTTCA</named-content> <named-content content-type="sequence">AGAAACCCAATCAGGCCTAC</named-content></td><td align="left" valign="bottom">All AURKA 5′UTR splice variants<xref ref-type="table-fn" rid="app1table1fn2"><sup>†</sup></xref> and only long 3′UTR APA isoform. Primer pair anneals to AURKA exon XI.</td></tr><tr><td align="left" valign="bottom">SDHA_F SDHA_R</td><td align="left" valign="bottom"><named-content content-type="sequence">TGGGAACAAGAGGGCATCTG</named-content> <named-content content-type="sequence">CCACCACTGCATCAAATTCA</named-content></td><td align="left" valign="bottom">All SDHA transcript variants (NM_004168.4, NM_001294332.2, NM_001330758.2). Primer pair anneals to SDHA cDNA exons II–III.</td></tr></tbody></table><table-wrap-foot><fn id="app1table1fn1"><label>*</label><p>Primer sequences from <xref ref-type="bibr" rid="bib37">Lin et al., 2016</xref>.</p></fn><fn id="app1table1fn2"><label>†</label><p>For accession numbers see <xref ref-type="bibr" rid="bib12">Cacioppo and Lindon, 2022</xref>.</p></fn></table-wrap-foot></table-wrap><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Assessment of DNA contamination of RNA extracts.</title><p>(<bold>A</bold>) Lack of genomic DNA (gDNA) contamination in RNA samples was assessed by PCR using Aurora Kinase A (AURKA)-specific primers. RNA extracts from U2OS cells electroporated with the indicated reporters (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) were used as template for the amplification reaction. An RNA extract from mock transfected U2OS cells used as negative control. gDNA from untransfected U2OS cells used as positive control. (<bold>B</bold>) Lack of plasmid DNA contamination in RNA samples was assessed by PCR using mCherry specific primers. RNA extracts from U2OS cells electroporated with the indicated reporters (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) were used as template for the amplification reaction. An RNA extract from mock transfected U2OS cells and gDNA from untransfected U2OS cells used as negative controls. pBI-mCherry plasmid (pBI-mCh) used as positive control template.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig1-v1.tif"/></fig><fig id="app1fig2" position="float"><label>Appendix 1—figure 2.</label><caption><title>Predicted targets on human genome of primer pairs used in this study.</title><p>Analysis performed using UCSC In-Silico PCR tool (<ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu/cgi-bin/hgPcr">https://genome.ucsc.edu/cgi-bin/hgPcr</ext-link>). Genomic PCR product of SDHA primer pairs is above &gt;850 bp length set for the in silico search.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig2-v1.tif"/></fig><fig id="app1fig3" position="float"><label>Appendix 1—figure 3.</label><caption><title>Validation of primer pairs used in RT-qPCR.</title><p>Standard curve, melt curve, and amplification plot of amplification reactions of serial dilutions (1:5) are shown. Sample reactions were loaded on gel to validate amplicon size. NTC, non-template control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig3-v1.tif"/></fig><fig id="app1fig4" position="float"><label>Appendix 1—figure 4.</label><caption><title>Validation of primer pairs used in RT-qPCR.</title><p>Standard curve, melt curve, and amplification plot of amplification reactions of serial dilutions (1:5) are shown. Sample reactions were loaded on gel to validate amplicon size. NTC, non-template control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig4-v1.tif"/></fig><fig id="app1fig5" position="float"><label>Appendix 1—figure 5.</label><caption><title>Validation of primer pairs used in RT-qPCR.</title><p>Standard curve, melt curve, and amplification plot of amplification reactions of serial dilutions (1:5) are shown. Sample reactions were loaded on gel to validate amplicon size. The target was also amplified from RNA extracts of cells transfected with the pBI-mCherry construct as neg. control (mCh). NTC, non-template control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig5-v1.tif"/></fig><fig id="app1fig6" position="float"><label>Appendix 1—figure 6.</label><caption><title>Validation of primer pairs used in RT-qPCR.</title><p>Standard curve, melt curve, and amplification plot of amplification reactions of serial dilutions (1:5) are shown. NTC, non-template control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig6-v1.tif"/></fig><fig id="app1fig7" position="float"><label>Appendix 1—figure 7.</label><caption><title>Validation of primer pairs used in RT-qPCR.</title><p>Standard curve, melt curve, and amplification plot of amplification reactions of serial dilutions (1:5) are shown. Sample reactions were loaded on gel to validate amplicon size. NTC, non-template control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig7-v1.tif"/></fig><fig id="app1fig8" position="float"><label>Appendix 1—figure 8.</label><caption><title>Validation of primer pairs used in RT-qPCR.</title><p>Standard curve, melt curve, and amplification plot of amplification reactions of serial dilutions (1:5) are shown. Sample reactions were loaded on gel to validate amplicon size. NTC, non-template control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig8-v1.tif"/></fig><fig id="app1fig9" position="float"><label>Appendix 1—figure 9.</label><caption><title>Validation of primer pairs used in RT-qPCR.</title><p>Standard curve, melt curve, and amplification plot of amplification reactions of serial dilutions (1:5) are shown. Sample reactions were loaded on gel to validate amplicon size. NTC, non-template control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig9-v1.tif"/></fig><fig id="app1fig10" position="float"><label>Appendix 1—figure 10.</label><caption><title>Validation of primer pairs used in RT-qPCR.</title><p>Standard curve, melt curve, and amplification plot of amplification reactions of serial dilutions (1:5) are shown. Sample reactions were loaded on gel to validate amplicon size. NTC, non-template control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig10-v1.tif"/></fig><fig id="app1fig11" position="float"><label>Appendix 1—figure 11.</label><caption><title>Validation of primer pairs used in RT-qPCR.</title><p>Standard curve, melt curve, and amplification plot of amplification reactions of serial dilutions (1:5) are shown. Sample reactions were loaded on gel to validate amplicon size. NTC, non-template control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87253-app1-fig11-v1.tif"/></fig><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>Reaction conditions and thermocycling parameters for one-step RT-qPCR.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="3">Reagent</th><th align="left" valign="bottom" colspan="2">Volume</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="3">Luna Universal One-Step Reaction Mix (2×)</td><td align="left" valign="bottom" colspan="2">10 µl</td></tr><tr><td align="left" valign="bottom" colspan="3">Luna WarmStart RT Enzyme Mix (20×)</td><td align="left" valign="bottom" colspan="2">1 µl</td></tr><tr><td align="left" valign="bottom" colspan="3">Forward primer (10 µM)</td><td align="left" valign="bottom" colspan="2">0.4 µl</td></tr><tr><td align="left" valign="bottom" colspan="3">Reverse primer (10 µM)</td><td align="left" valign="bottom" colspan="2">0.4 µl</td></tr><tr><td align="left" valign="bottom" colspan="3">Template RNA</td><td align="left" valign="bottom" colspan="2">&lt;100 ng</td></tr><tr><td align="left" valign="bottom" colspan="3">Nuclease-free water</td><td align="left" valign="bottom" colspan="2">Up to 20 µl</td></tr><tr><td align="left" valign="bottom" colspan="5">MicroAmp Fast Optical 96-Well Reaction Plate with Barcode, 0.1 ml (Thermo Fisher, 4346906)</td></tr><tr><td align="left" valign="bottom"><bold>Cycling step</bold></td><td align="left" valign="bottom"><bold>Temperature (°C)</bold></td><td align="left" valign="bottom" colspan="2"><bold>Time</bold></td><td align="left" valign="bottom"><bold>Cycles</bold></td></tr><tr><td align="left" valign="bottom">Reverse transcription</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom" colspan="2">10 min</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Initial denaturation</td><td align="left" valign="bottom">95</td><td align="left" valign="bottom" colspan="2">1 min</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Denaturation extension</td><td align="left" valign="bottom">95<break/>–60</td><td align="left" valign="bottom" colspan="2">10 s<break/>1 min</td><td align="left" valign="bottom">40</td></tr><tr><td align="left" valign="bottom">Melt curve</td><td align="left" valign="bottom">60–95</td><td align="left" valign="bottom" colspan="2">-</td><td align="left" valign="bottom">1</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87253.2.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Topisirovic</surname><given-names>Ivan</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056jjra10</institution-id><institution>Jewish General Hospital</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>In this <bold>important</bold> study, the authors provide <bold>compelling</bold> evidence that the interplay between alternative polyadenylation (APA) of mRNA encoding Aurora Kinase A (AURKA) and <italic>hsa-let-7a</italic> miRNA governs AURKA protein levels. The authors show that short 3'UTR isoform of mRNA encoding AURKA is efficiently translated throughout the cell cycle, while the long 3'UTR isoform is suppressed by <italic>hsa-let-7a</italic> miRNA in a cell cycle-dependent manner. These findings delineate post-transcriptional mechanisms regulating AURKA expression that may be implicated in increase in AURKA protein that is frequently observed across a variety of cancers.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87253.2.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In this article, Cacioppo et al., report on a previously unappreciated mechanism of the regulation of Aurora Kinase A (AURKA) protein levels that is orchestrated via coordinated action of alternative polyadenylation of AURKA mRNA and hsa-let-7a miRNA. Moreover, it is proposed that this mechanism may play a major role in neoplasia. In support of their model, the authors demonstrate that short-to-long 3'UTR AURKA mRNA isoform ratio is elevated in triple negative breast cancer patients where it correlates with poor prognosis. The authors further generated reporters suitable for single cell live imaging that express different 3'UTR variants, which revealed highly variable ratios of short and long 3'UTR AURKA isoforms across different cell lines. This was followed by actinomycin D chase and nascent chain immunoprecipitation assays in U2OS osteosarcoma cells to demonstrate that while short and long 3'UTR AURKA isoforms have comparable stability, short 3'UTR AURKA isoforms appear to exhibit higher ribosome association which is indicative of higher translation activity. Furthermore, using an additional reporter assay which takes advantage of trimethoprim-based stabilization of highly unstable <italic>E. coli</italic> dihydrofolate reductase mutants Cacioppo et al., provide evidence that in contrast to the short 3'UTR AURKA mRNA isoform which appears to be constitutively translated throughout the cell cycle, long 3'UTR AURKA mRNA isoform is preferentially translated in the G2 phase. Further evidence is provided that suppression of long 3'UTR AURKA mRNA isoform is at least in part mediated by hsa-let-7a miRNA. Finally, the authors provide evidence that disrupting the expression of long 3'UTR AURKA mRNA isoform using CRISPR-based strategy, leads to overexpression of AURKA driven by the short 3'UTR isoform which is paralleled by an increase in cancer-related phenotypes.</p><p>Strengths: Overall it was thought that this study is of potentially broad interest inasmuch as it delineates a hitherto unappreciated mechanisms of regulation of AURKA protein levels, whereby AURKA is emerging as one of the major factors in neoplasia, including resistance to anti-cancer treatments. In general, it was thought that the author's conclusions were sufficiently supported by provided data. It was also thought that this study incorporates innovative methodology including single-cell expression sensors coupled with live cell microscopy and an assay to study translation in different phases of cell cycle without need for cell synchronization.</p><p>Weaknesses: Several relatively minor issues were observed regarding methodology and data interpretation. Namely, some inconsistencies between the models and/or cell lines that were used throughout the manuscript were noted. For instance, key experiments were performed almost exclusively in U2OS osteosarcoma cells, whereby triple negative breast cancer patient data were used to set the scientific foundation of the study. Considering potential differences in alternative polyadenylation between cell and tissue types, it was thought that investigation across the broader compendium of cell lines may be required for generalization of findings observed in U2OS cells. It was also found that the precise mechanisms underpinning the role of hsa-let-7a miRNA in regulation of AURKA protein levels remain largely obscure.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87253.2.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Cacioppo et al describe a mechanism of translation regulation of Aurora A, which is dependent on alternative polyadenylation. They suggest that altered expression of the resulting isoforms in cancers is at least partly responsible for elevated Aurora A levels, which in turn is known to indicate poor prognosis.</p><p>The authors exploit publicly available databases and patient data to highlight the correlation of increased abundance of the SHORT isoform (relative to the LONG one) and poor patient survival in TNBC, as well as breast and lung cancer.</p><p>In their thorough mechanistic study they use a number of reporters to assess the impact of alternative polyadenylation on mRNA stability and translation efficiency and explore whether this process accounts for cell-cycle-regulated expression of Aurora A. These reporters are carefully controlled and well explained. I particularly commend the authors for the clear graphical presentations of the reporters (eg fig 2A, fig 3D, fig 4A). Rigorous control experiments are performed to make sure that the reporters work and &quot;report&quot; what they are meant to do, and to show that previous findings can be reproduced in experiments based on the reporters (eg higher protein expression from the short 3' UTR APA isoform of CDC6 mRNA, targeting of MZF1 3'UTR by hsa-let-7a).</p><p>They show that translation of the longer isoform is subject to suppression by hsa-let-7a, while the shorter isoform is not. They attribute cell-cycle regulated expression of Aurora A at least in part to the suppression of translation of the LONG isoform in G1 and S.</p><p>In Figure 6 they address whether the APA-based regulatory mechanism alters Aurora A levels sufficiently to confer features associated with oncogenic transformation and overexpression of Aurora A. These data nicely tie together the observations in databases and the mechanistic part of the study.</p><p>The logic is clear and the conclusions are well supported by the data.</p><p>The authors state themselves that the impact of translation regulation on Aurora A levels in the cell cycle is an important but unanswered question. The evidence that suppression of translation of the LONG transcript contributes to the cell-cycle regulation of Aurora A is convincing, but the extent could be explored further. I wonder whether published genome-wide studies (eg PMCID 4548207, PMC3959127) have relevant data on the translation rate of Aurora A in the cell cycle.</p><p>In the paper this question is addressed in cells enriched in G1/S (Fig 6) and using the reporters (Fig 5). Having generated the ΔdPAS mutants, Aurora A levels could be easily assessed in each cell-cycle phase. The best way to do this would be sorting followed by immunoblotting.</p><p>The fact that Aurora A levels are reduced by a 6h treatment with 0.1 mg/ml CHX (Fig 6D) is interpreted as &quot;AURKA expression in G1/S was reduced in the mutated cell lines when treated with CHX, indicating that translation of the short isoform is active in this phase&quot; It is rather expected that using a translation inhibitor will stop the accumulation of a protein and so this experiment does not add much. A better approach to address the effect of the mutations on translation would be to add a proteasome inhibitor and follow accumulation of Aurora A, preferably not only in G1/S but also in other cell-cycle phases. Accumulation of the protein in this experiment would better reflect translation rates.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87253.2.sa3</article-id><title-group><article-title>Reviewer #3 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This manuscript sheds light on the cell cycle-dependent post-transcriptional regulation of the oncogenic kinase AURKA. AURKA mRNA is subjected to alternative polyadenylation (APA), resulting in a short and a long 3'UTR isoform. While the ratio long/short isoform is important for AURKA expression and might impact cancer development, it is not unclear how this is regulated throughout the cell cycle. Translation and decay rate of the long isoform only are targeted by let-7a miRNA and in a cell-cycle dependent manner. In contrast, the short isoform is translated highly and constantly throughout interphase. Finally, depletion of the long isoform led to an increase in proliferation and migration rates of cells. In Triple Negative Breast Cancer, where AURKA is typically overexpressed, the short isoform is predominant and its expression correlates with faster relapse times of patients, suggesting that this mechanism might play an important role in this cancer.</p><p>Originality and novelty:</p><p>The originality of this work is to show the cooperation between APA and miRNA-targeting in controlling gene expression dynamics of AURKA during cell cycle. To investigate this mechanism, the authors have developed an interesting transient single-cell and biochemical assay to rapidly study mRNA-specific gene expression in a way that measures post-transcriptional events. This manuscript puts an emphasis on the cell cycle dependent expression control of AURKA at the translation level. However, the magnitude of the changes in mRNA levels throughout the cell cycle is even greater than that of the changes in translation. Therefore, it remains unclear whether translation really is that important in controlling AURKA expression during the cell cycle. Moreover, (i) AURKA regulation by miRNA is already known (Fadaka et al., Oncotarget 2020, Zhang et al., Arch Med Sci 2020, Yuan et al., Technol Cancer Res Treat 2019, Ma et al., Oncotarget 2015), (ii) the concept of cooperation between APA and translation already is not new (Sandberg et al., Science 2008, Mayr and Bartel, Cell 2009, Masamha et al. Nature 2015), and (iii) previous transcriptome-wide studies already suggested a cell-cycle dependent control of AURKA at the translation level (Tanenbaun et al., eLife 2015, translation efficiency ratio G2/G1 = 1.59) as well as the mRNA level (Krenning et al., eLife 2022). The impact of this manuscript could be increased by investigating (i) the mechanism of cell cycle-dependent regulation by let7a expression (i.e is there changes in let7a expression or activity during the cell cycle in this model) and (ii) the origin of AURKA APA dysregulation in cancer (could it be modulated by CFIm25? (Masamha et al. Nature 2015, Tamaddon et al. Sci Rep 2020)).</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87253.2.sa4</article-id><title-group><article-title>Author Response:</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cacioppo</surname><given-names>Roberta</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Akman</surname><given-names>Hesna Begum</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Tuncer</surname><given-names>Taner</given-names></name><role specific-use="author">Author</role><aff><institution>Ondokuz Mayis Universitesi</institution><addr-line><named-content content-type="city">Samsun</named-content></addr-line><country>Turkey</country></aff></contrib><contrib contrib-type="author"><name><surname>Erson-Bensan</surname><given-names>Ayse Elif</given-names></name><role specific-use="author">Author</role><aff><institution>METU</institution><addr-line><named-content content-type="city">Ankara</named-content></addr-line><country>Turkey</country></aff></contrib><contrib contrib-type="author"><name><surname>Lindon</surname><given-names>Catherine</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><p>We thank the editors and reviewers for their assessment of our manuscript, and their agreement that we present compelling evidence for post-transcriptional regulation of AURKA through the 3’UTR.</p><p>In response to Reviewer 1, we acknowledge that much of our study is performed exclusively in U2OS cells, and that study of alternative polyadenylation in additional cell lines would serve to further generalize our findings. However, as U2OS are a well-known model cell line for cell cycle studies we believe our demonstration of cell cycle regulation of AURKA through its 3’UTR offers a depth of understanding that is perhaps of greater interest than confirming the existence of alternative AURKA 3’UTRs in additional cell lines, using our methods. We note that the recent rapid growth in RNA seq data resources allows easy confirmation of the broad existence of alternative polyadenylation events on a genome-wide scale. For example, AURKA-specific data extracted from a recent benchmark study of Nanopore long read RNA sequencing (Chen et al., 2021) clearly shows the existence of two distinct AURKA 3’UTRs differentially expressed between a number of different cancer cell lines. In addition, a recent study investigating the landscape of APA at single-cell resolution detected AURKA APA isoforms in HeLa and MDA-MB-468 cell lines (Wang et al., 2022). Their study further identifies AURKA among genes showing negative correlation between generalized distal polyA site usage index (gDPAU) and expression levels, meaning preference to use the proximal polyA site when expression levels increase, and include AURKA in the gene cluster showing slight increase in usage of the distal polyA site from G1 to M phase (Wang et al., 2022). Both studies are in support of the evidence presented in our manuscript.</p><p>We agree with Reviewer 2 that better information on translation rates would improve our understanding of the impact of translation regulation on AURKA levels. Some insight on the translation rate of AURKA in the cell cycle can be derived from inspection of the ribosome profiling dataset published by Tanenbaum et al., 2015. From their analysis, translation efficiency of AURKA mRNA in G2 is 1.59 times that in G1 and in G1 it is 0.69 times that in M phase, whilst in G2 it is 1.10 times higher than in M. Such data reveal a reversible increase in translation of AURKA mRNA, alongside other mitotic regulators, in preparation for M phase (Tanenbaum et al., 2015). These results are in accordance with our findings that translation rates contribute modestly to cell cycle changes in AURKA levels in normal cells, and we concur with Reviewer 3’s comment that the contribution of increased translation rate to AURKA levels at mitosis is less than the change in mRNA levels at this point in the cell cycle.</p><p>We think the significance of the regulatory mechanism we describe lies rather in the large effect it has on AURKA levels in interphase (when AURKA expression is normally repressed at both mRNA and translation rate). We hypothesise that it is interphase regulation that may be relevant to roles of AURKA in cancer (and to the association of APA with cancer) (Bertolin and Tramier, 2020; Naso et al., 2021). It is indeed the case that (i) AURKA regulation by miRNA, (ii) cooperation between APA and translation and (iii) cell-cycle dependent control of AURKA at the translation level, are already known. We believe the novelty of our study lies in drawing together these elements to provide new insight into AURKA regulation, using tools that allow similar investigation of other APA events, and contributing new ideas for future therapeutic interventions for disease proteins regulated via APA.</p><list list-type="bullet"><list-item><p>Bertolin and Tramier (2020), Cell. Mol. Life Sci <ext-link ext-link-type="uri" xlink:href="https://link.springer.com/article/10.1007/s00018-019-03310-2">https://link.springer.com/article/10.1007/s00018-019-03310-2</ext-link></p></list-item><list-item><p>Chen et al. (2021), bioRxiv <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.04.21.440736v1">https://www.biorxiv.org/content/10.1101/2021.04.21.440736v1</ext-link></p></list-item><list-item><p>Naso et al. (2021), Oncogene <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41388-021-01766-w">https://www.nature.com/articles/s41388-021-01766-w</ext-link></p></list-item><list-item><p>Tanenbaum et al. (2015), eLife <ext-link ext-link-type="uri" xlink:href="https://elifesciences.org/articles/07957">https://elifesciences.org/articles/07957</ext-link></p></list-item><list-item><p>Wang et al. (2022), PNAS <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/doi/10.1073/pnas.2113504119">https://www.pnas.org/doi/10.1073/pnas.2113504119</ext-link></p></list-item></list></body></sub-article></article>